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Abstract
Perfluorinated compounds [PFCs] have found a wide use in industrial products and processes and in a vast array of
consumer products. PFCs are molecules made up of carbon chains to which fluorine atoms are bound. Due to the
strength of the carbon/fluorine bond, the molecules are chemically very stable and are highly resistant to
biological degradation; therefore, they belong to a class of compounds that tend to persist in the environment.
These compounds can bioaccumulate and also undergo biomagnification. Within the class of PFC chemicals,
perfluorooctanoic acid and perfluorosulphonic acid are generally considered reference substances. Meanwhile, PFCs
can be detected almost ubiquitously, e.g., in water, plants, different kinds of foodstuffs, in animals such as fish,
birds, in mammals, as well as in human breast milk and blood. PFCs are proposed as a new class of ‘persistent
organic pollutants’. Numerous publications allude to the negative effects of PFCs on human health. The following
review describes both external and internal exposures to PFCs, the toxicokinetics (uptake, distribution, metabolism,
excretion), and the toxicodynamics (acute toxicity, subacute and subchronic toxicities, chronic toxicity including
carcinogenesis, genotoxicity and epigenetic effects, reproductive and developmental toxicities, neurotoxicity, effects
on the endocrine system, immunotoxicity and potential modes of action, combinational effects, and
epidemiological studies on perfluorinated compounds).
Keywords: PFCs, PFOA, PFOS, toxicology
Introduction
Perfluorinated compounds [PFCs] are organic sub-
stances in which all of the hydrogens of the hydrocar-
bon backbones are substituted with fluorine atoms. The
fluorine-carbon bonds are extremely stabile conferring
these substances with very high thermal and chemical
stability. PFCs are persistent, and some of the sub-
stances bioaccumulate in the environment.
They can be divided into the groups of perfluorinated
sulfonic acids, perfluorinated carboxylic acids [PFCA],
fluorotelomer alcohols, high-molecular weight fluoropo-
lymers and low-molecular weight perfluoroalkanamides.
Perfluorooctanesulfonic acid [PFOS] and perfluoroocta-
noic acid [PFOA], often referred to as reference or key
substances for the first two groups, have been most
intensively studied from a toxicological standpoint.
PFCs have been synthesized for more than 50 years
and are used in numerous industrial and consumer pro-
ducts. These compounds are intermediates or additives
in the synthesis of certain fluorine compounds or their
decomposition products. These fluorine compounds are
commonly used in consumer products as stain/water/
grease repellents in carpets and clothing or in cooking
utensils as nonstick coatings [1,2].
The potentially toxic effects of these substances are
presently being studied with increasing intensity. The
relevance of this topic is also clearly reflected by the
number of publications that have appeared in recent
years. This increasing interest is the result of reports of
toxic effects of PFCs in connection with the ubiquitous
detection of this substance in the environment and in
sundry matrices, i.e., bodies of water, wild animals,
human blood, and breast milk samples, all of which
have come to the attention of the public.
An estimate was published in 2008 by the German
Federal Institute for Risk Assessment [BfR] and the Eur-
opean Food Safety Authority [EFSA] regarding the
potential risks of PFCs in food stuffs for human health.
In this document, it was reasoned that adverse effects
for the general population were unlikely, based on the
known PFC concentrations in food stuffs and serum
samples and the present state of scientific knowledge.
However, uncertainty was noted in the risk evaluation,
and available data are inadequate in regard to the
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diversity of foodstuffs. In addition, only PFOS and
PFOA were considered in the risk evaluation, but
according to the Organisation for Economic Co-opera-
tion and Development [OECD], 853 different poly- and
perfluorinated compounds exist [3,4].
In a European Union [EU]-supported research project,
which began in August 2009 and was called Perfluori-
nated Organic compounds in our Food [PERFOOD],
efforts are being made to estimate the dietary exposure
to PFCs. The present review summarizes current data
on exposure and provides an overview of the present
toxicological evaluation of PFOS and PFOA, as well as
other PFCs.
Exposure to polyfluorinated compounds
Exposure via the food chain
Dietary uptake
One of the pathways by which PFCs can be taken up is
through the ingestion of contaminated foodstuffs and/or
drinking water. PFCs have been detected in fish, meat,
milk products, and plants, e.g., grains. Plants can appar-
ently take up PFCs from contaminated soil. This
hypothesis was examined by Weinfurtner et al. [5],
showing that the transfer of PFCs from the soil to the
plants for potatoes, silage corn, and wheat was so mar-
ginal that no health danger for humans would be
expected by this path of uptake.
Stahl et al. [6] described for the first time a significant,
concentration-dependent transfer (’carry over’) of PFCs
from the soil to the plant. The higher the concentration
of PFOA and PFOS in the soil, the higher the concen-
tration that could be detected in the plants. The uptake
and storage of these substances in the vegetative parts
of the plants appear to be more significant than the
transfer to the storage organs within the plants. In this
study, the uptake, distribution, and storage of PFOA and
PFOS were seen to be dependent upon the type of plant.
The uptake of PFOA and PFOS from contaminated soil
by plants enables the entrance of PFCs into the food
chain of humans and may provide an explanation for
the presence of these compounds in, for example, food-
stuffs of animal origin, human blood samples, and
human breast milk [6].
Trudel et al. [7] reported that oral ingestion of con-
taminated foodstuffs and drinking water accounts for
the largest proportion of PFOA and PFOS exposures for
adults. Tittlemier et al. [8] and Haug et al. [9,10] also
expressed the opinion that foodstuffs are the most
important uptake path. Within the framework of the
‘Canadian Total Diet Study, ‘ the authors calculated that
Canadians ingest on an average of 250 ng of PFCA and
PFOS per day. Scheringer et al. [11] also had come to
the conclusion that 90% of all PFOS and PFOA expo-
sures is derived from food. Similarly, Vestergren and
Cousins [12] are convinced that the main exposure of
humans to PFOA is through dietary uptake.
Fromme et al. [13] quantified PFC dietary exposure in
Germany. The authors collected and analyzed 214 dupli-
cate meals and beverages from 31 volunteers aged 16 to
45 years old on 7 days in a row. The samples were
tested for content of numerous PFCs. The results for
PFOS and PFOA uptake of the general population are
presented in Table 1.
Perfluorohexane sulfonate [PFHxS] and perfluorohex-
ane acid [PFHxA] levels above the limit of detection
[LOD] of 0.1 or 0.2 μg/kg fresh weight, respectively,
were detected in only a few samples (3% and 9% of the
214 samples, respectively), whereas perfluorooctane sul-
fonamide FOSA] was not detected (LOD = 0.2 μg/kg
fresh weight). These authors also assume that dietary
uptake represents the main source of PFC exposure for
humans [13].
Numerous foodstuffs were tested for the presence of
PFOS, PFOA, and other PFCs within the framework of
the ‘UK Total Diet Study’ in 2004. PFOS concentrations
above the LODa were detected in potatoes, canned vege-
tables, eggs, sugar, and preserves. Particularly striking
was the group of potato products, where in addition to
PFOD, PFOA and 10 other PFCs were detected. The
upper and lower bounds of total PFOS and PFOA
uptake from foodstuffs are estimated in Table 2[14,15].
Inhabitants of reputedly remote regions are by no
means exempt from the uptake of PFCs in their food. In
a recent study, Ostertag et al. [16] examined the dietary
exposure of Inuit in Nunavut (Canada) to these sub-
stances. The authors calculated an average daily expo-
sure of 210 to 610 ng/person. The traditional foods
such as caribou meat contributed to a higher PFC expo-
sure for this population group. Caribou meat contribu-
ted 43% to 75% of the daily exposure [16].
In 2008, an exposure assessment was made on dietary
uptake of PFOS and PFOA in connection with possible
health effects. The report was based on published data
concerning concentrations of PFOS and PFOA in var-
ious foods in Europe and on the amount of the indivi-
dual foods consumed according to the ‘Concise
European Food Consumption Database’ [15]. Since the
data for other foods were inadequate to make an expo-
sure assessment, it was based solely on the presence of
PFOS and PFOA in fish and drinking water. The results
Table 1 Dietary uptake of PFOS and PFOA (ng/kg BW/
day) by adults in Germany
Substance Range Mean Average 90th percentile
PFOS 0.6 to 4.4 1.4 1.8 3.8
PFOA 1.1 to 11.6 2.9 3.9 8.4
Adapted from Fromme et al. [13]; n = 214.
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of the exposure assessment for PFOS suggest a daily
exposure of 60 ng/kg body weight [BW] for persons
who consume average amounts of fish or 200 ng/kg BW
those who consume large amounts of fish. For PFOA,
the daily uptake was estimated at 2 ng/kg BW/day, and
for those who eat larger amounts of fish and fish pro-
ducts, the estimate was 6 ng/kg BW/day [15].
The estimated consumption of drinking water was 2
L/person/day. The uptake from drinking water of PFOS
and PFOA were ca. 0.5% and 18%, respectively, of the
average amount taken up by consumption of fish and
fish products. For further details, see Table 3.
The German BfR [17] also undertook an assessment of
dietary exposure of the general population to PFOS and
PFOA. As a basis for the calculations, the Federal Office
of Consumer Protection and Food Safety provided data
on PFC concentrations in foods from 2006 to 2008. The
data were, for the most part, derived from the Federal
Control Plan (2007) ‘Perfluorinated surfactants in speci-
fic foods’ and encompassed 3, 983 test results on con-
tents of PFOS (1993 data sets) and PFOA (1990 data
sets) in foodstuffs. Concentrations of the substances
were measured in chicken eggs, beef and poultry liver,
pork, game and fish offal, poultry and game meat, salt
water and fresh water fish, French fries, honey, and
drinking water. In addition, the records contained data
on the consumption of food and food products by the
German population derived from a survey made in
1998. Since one must assume that for over a longer per-
iod of time, some foods that have a higher PFC concen-
tration and others with a lower concentration will be
consumed, the statistical calculations were made using
an averageb value. In addition, the possibility had to be
considered that foods that have exceptionally high
concentrations may be consumed perhaps because of
unusual local paths of entry. Therefore, exposure
through particularly heavily contaminated foods was
quantified for both average and above average consu-
mers. The following scenarios were assumed for expo-
sure assessment:
• Average concentration of PFOS and/or PFOA and
average amounts consumed
• High concentration of PFOS and/or PFOA and
average amounts consumed
• Average concentration of PFOS and/or PFOA and
large amounts consumed
• High concentrations of PFOS and/or PFOA and
large amounts consumed (worst case).
The PFOS and PFOA dietary uptake of the general
population, divided into the four scenarios described
above, can be seen in Table 4. In addition, the table
shows the percentage of the EFSA-derived tolerable
daily intake [TDI] calculated for PFOS and PFOA
uptake.
In this exposure assessment, drinking water played a
relatively small role in the total exposure to PFOS. The
average PFOS uptake from drinking water by an average
consumer amounted from 0.02 to 0.08 ng/kg BW/day.
The average PFOA uptake from drinking water, how-
ever, amounted from 0.32 to 0.40 ng/kg BW/day. Thus,
the total PFOA uptake, including drinking water,
amounted from 1.03 to 1.34 ng/kg BW/day for an aver-
age consumer [17]. If, however, the water is contami-
nated by an unusual source of PFCs, the role of
drinking water in exposure to these substances may be
considerable. This was the case, for example, in Arns-
berg, Germany where the source of drinking water in
2006 was the PFC-contaminated river, Möhne [18]. Höl-
zer et al. [19] measured a PFOA concentration 4.5 to
8.3 times higher in the blood plasma of residents than
in the plasma of a reference population from the neigh-
boring towns, Siegen and Brilon. The mean concentra-
tions of PFOA in the blood are shown in Table 5. The
highest PFC concentration detected in the contaminated
drinking water was for PFOA [19].
Table 2 PFOS and PFOA uptake (ng/kg BW/day) from UK
Total Diet Study of adults and children
Substance Average consumption Heavy consumption
Adults Childrena Adults Childrena
PFOS 10 to 100 50 to 300 30 to 200 100 to 500
PFOA 1 to 70 4 to 200 3 to 100 10 to 300
aIn each case, the age group with the highest estimated uptake is listed.
Adapted from UK FSA [14]; EFSA [15].
Table 3 PFOS and PFOA uptake through consumption of drinking water and fish and fish products
Substance and percentage of
uptake from drinking water
Uptake from
drinking water
Uptake from average consumption of fish
and fish products (ng/kg BW/day)
Uptake from high consumption of fish
and fish products (ng/kg BW/day)
PFOS 0.24 45 to 58 140 to 230
Percentage of uptake from
drinking water
0.4% to 0.5% 0.1% to 0.2%
PFOA 0.31 1.7 to 2.1 4.5 to 7.5
Percentage of uptake from
drinking water
15% to 18% 4% to 7%
Adapted from EFSA [15].
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In a follow-up study, it was shown that elimination of
PFCs from humans occurs slowly. The geometric mean
of the PFOA concentrations in plasma decreased on an
average of 10% per year for men, 17% per year for
women, and 20% per year for children [20].
Another study showed that there was no increased
PFC exposure in this region in 2006 before contamina-
tion of the drinking water. Samples of blood from 30
residents that had been drawn between 1997 and 2004
contained PFOS and PFOA concentrations comparable
with those of the general population in Germany [21].
After concentrations as high as 0.64 μg/L were mea-
sured in drinking water in Arnsberg in 2006, the Ger-
man Drinking Water Commission derived a critical
limit of 0.3 μg/L for a health-based, lifelong exposure to
PFOS and PFOA in drinking water. PFOS and PFOA
concentrations in drinking water can be reduced by
active charcoal filtration. Use and manufacture of PFOS
are strictly limited by legal regulation, and a voluntary
reduction of PFOA is being sought. Therefore, the focus
of a study by Wilhelm et al. [22] was placed on short-
chain C4-C7 compounds that are presently finding use
as substitutes for PFOS and PFOA. In a new approach
to evaluate short-chain PFCs, based on their half-life in
humans, the following preliminary health-related indica-
tion values were considered safe for a lifelong exposure
via drinking water: 7 μg/L for perfluorobutanoic acid
[PFBA], 3 μg/L for perfluoro-n-pentanoic acid [PFPeA],
1 μg/L for PFHxA, 0.3 μg/L for perfluoroheptanoic acid
[PFHpA], 3 μg/L for perfluorobutanesulfonic acid
[PFBS], 1 μg/L for perfluoropentane-1-sulfonic acid
[PFPeS], 0.3 μg/L for PFHxS, and 0.3 μg/L for perfluoro-
heptane sulfonic acid [PFHpS]. A long-range minimum
quality goal or general precautionary value for all PFCs
in drinking water was set at ≤ 0.1 μg/L [22].
A study by Mak et al. [23] compared PFC concentra-
tions in tap water from China with that from Japan,
India, the USA, and Canada. Samples were collected
between 2006 and 2008. Tap water from Shanghai,
China contained the highest concentration of PFCs
(arithmetic mean sum PFCs 0.13 μg/L; PFOA 0.078 μg/
L). The lowest values were obtained from Toyama,
Japan (0.00062 μg/L). In addition to PFOS and PFOA,
drinking water appears to also contain short-chain PFCs
such as PFHxS, PFBS, PFHxA, and PFBA. In relation to
the guidelines set down by the United States Environ-
mental Protection Agency [US EPA] and the Minnesota
Department of Health (PFOS 0.2 μg/L, PFOA 0.4 μg/L,
PFBA 1.0 μg/L, PFHxS 0.6 μg/L, PFBS 0.6 μg/L, PFHxA
1.0 μg/L, PFPeA 1.0 μg/L), tap water from these coun-
tries should not present a health risk for consumers, in
respect to PFC contamination [23].
In a review article from Rumsby et al. [24] on PFOS
and PFOA in drinking water and in diverse environmen-
tal bodies of water, the authors also conclude that PFOS
and PFOA are detectable worldwide. Aside from situa-
tions in which there are unusual sources of contamina-
tion, the concentrations measured are, however, below
existing health-based guidelines specified by various
international bodies (0.3 to 0.5 μg/L). Nonetheless,
further studies of short-chain PFCs such as PFBS must
be undertaken. This substance has a shorter half-life, is
less toxic, and is not bioaccumulative, but it is nonethe-
less persistent, and its possible degradation products
remain unknown [24].
D’Eon et al. [25] point out that perfluorinated phos-
phonic acids [PFPAs] should also be measured in future
environmental monitoring studies. These substances
were detected in 80% of all surface water samples and
in six out of seven sewage treatment plant outflow sam-
ples in Canada. C8-PFPA was detected in concentrations
from 0.088 ± 0.033 to 3.4 ± 0.9 ng/L in surface water
and from 0.76 ± 0.27 to 2.5 ± 0.32 ng/L in sewage treat-
ment plant outflow samples. Since they are structurally
similar, one can assume that just like perfluorocarboxilic
acids and perfluorosulfonic acids, PFPAs are also persis-
tent [25].
Human exposure via fish consumption
In addition to drinking water, PFC accumulation in fish
is also of particular importance for the internal contami-
nation of humans. According to the exposure assess-
ment of the German BfR consumption of salt water and
Table 4 PFOS and PFOA dietary exposure model (ng/kg
BW/day) according to uptake scenarios and
corresponding TDI
Criterion Average consumption High consumptionb
Average PFOS content 2.30 to 3.69 up to 8.92
Percentage of TDIa 1.5% to 2.5% 5.9%
High PFOS content 8.53 to 10.22 up to 26.02
Percentage of TDI 5.7% to 6.8% 17.3%
Average PFOA content 0.71 to 0.95 up to 2.07
Percentage of TDI 0.05% to 0.06% 0.14%
High PFOA content up to 5.7 up to 13.11
Percentage of TDI 0.38% 0.87%
aTDI for PFOS = 150 ng/kg BW/day, TDI for PFOA = 1, 500 ng/kg BW/day
(adapted from EFSA [15]); bthe 95th percentile of the assumed amount of
consumption was chosen for the calculation. The model calculation was
adapted from BfR [17].
Table 5 Arithmetic/geometric mean of PFOS
concentration in the blood (μg/L)




Residents of Arnsberg were compared with the reference population (adapted
from Hölzer et al. [19]).
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fresh water, fish accounts for approximately 90% of the
total dietary exposure to PFOS [17].
The fact that fish are often highly contaminated is a
result of the pronounced biomagnification of these sub-
stances via the aquatic food chain. The role of fish con-
sumption is apparent in a model calculation by Stahl et
al. [26]. Based on the recommendation of the BfR of 0.1
μg PFOS/kg BW/day as a preliminary daily tolerable
uptake, a 70-kg adult should not exceed 7 μg of PFOS
[26]. Eating reasonable amounts of fish with high levels
of contamination, i.e., from bodies of water with unusual
sources of PFCs, may in itself result in reaching or
exceeding this limit for the short term [26]. For exam-
ple, eating 8 g of eel from Belgium with a concentration
of 857 μg PFOS/kg fresh weight or eating 0.6 g of trout
from the upper Sauerland region of Germany with a
measured maximum level of 1, 118 μg/kg fresh weight,
is already adequate. Consumption of a normal portion
(300 g) of these trout would result in exceeding the
limit by a factor of 57 [26]. PFC contamination of fish
was also dealt within the following studies:
As an example, analysis was made from a total of 51
eels, 44 bream, 5 herring, 5 mackerel, 3 carp, and 4
trout from various bodies of water in Germany (North
Sea, Baltic Sea, Lake Storko in Brandenburg, rivers in
Lower Saxony, rivers and lakes within the city limits of
Berlin). None of the fish fillet samples had PFOA levels
above the limit of detection (0.27 μg/kg); however,
PFOS concentrations of 8.2 to 225 μg/kg fresh weight
were measured in fish from densely populated regions.
With regard to the TDI of 150 μg/kg BW/day [15] and
assuming the consumption of fish on a regular basis, the
PFC concentrations in 33 of the 112 fish examined
represent a potential health risk to heavy consumers of
fish [27].
In a Swedish study, the authors also came to the con-
clusion that consumption of fish from fishing grounds
with high concentrations of PFCs in the water can play
an important role in dietary PFOS exposure [28]. Fish
from Lake Vättern (mean 2.9 to 12 μg/kg fresh weight)
had higher PFOS concentrations in the muscle tissue
than fish from the brackish water of the Baltic Sea
(mean 1.0 to 2.5 μg/kg fresh weight). A PFOS uptake of
0.15 ng/kg BW/day was estimated for a moderate con-
sumption (two portions of 125 g/month) and 0.62 ng/kg
BW/day for a higher consumption (eight portions per
month) of fish from the Baltic Sea. A PFOS uptake of
2.7 ng/kg BW/day was calculated for people who eat
large amounts of fish from Lake Vättern.
No foods that have been examined to date other than
fish were found to have a level of contamination great
enough to result in reaching the TDI for PFOS or
PFOA, assuming realistic consumed amounts. By way of
example, according to the model calculations shown
above, an adult in the USA would have to consume 12
kg of beef (0.587 μg PFOS/kg) or 12 L of milk (0.693 μg
PFOS/L) per day (at the measured levels of contamina-
tion in the USA) in order to reach the TDI [26].
Furthermore, offal from game contained the highest
concentrations of PFOS and PFOA of all foods. The
PFOS concentrations in offal from game were 100-fold
higher than those in muscle tissues [17]. Data from a
number of studies reporting PFC concentrations mea-
sured in diverse foods and tap water [7,14,17,29] are
summarized in Table 6.
A detailed, up-to-date survey on the presence of PFCs
in foods was also recently published by the EFSA [30]
with the title ‘Results of the monitoring of perfluor-
oalkylated substances in food in the period 2000 to
2009.’
When making an exposure assessment, it is important
to take into account the fact that many different foods
are generally consumed. Studies with the aim of repre-
senting the total dietary intake are both quantitatively
and qualitatively inadequate. For example, in the various
studies including those of the EFSA and the BfR, only a
selection of foods were included. In addition, the number
of samples was, in part, too small to provide a representa-
tive value. For these reasons, the exposure assessments
presently available should be considered exploratory.
Specific regional sources of contamination can increase
PFC levels in foods and drinking water. Furthermore,
individual dietary habits, i.e., a predilection for fish or
offal from game, must be considered, and additionally,
perfluorinated compounds other than PFOS and PFOA
must be monitored. Since most studies have examined
fresh and unpackaged foods, the effects of migration of
PFCs from packaging and cooking utensils on the food
products have not been taken into consideration.
Exposure of food to food contact materials
When coming into contact with foods, paper and card-
board packaging are protected from softening by treat-
ment with, among other things, water- and oil-resistant
perfluoro chemicals. Fluorotelomer alcohols [FTOH]
may be present as contaminants in the coatings. About
1% of the FTOH can be converted to PFOA in the
body [31,32]. Furthermore, PFOA is used in the produc-
tion of polytetrafluoroethylene [PTFE] nonstick surface
coatings for cooking utensils or paper coatings and may
therefore be present in residual amounts [33]. A migra-
tion of < 6 μg/kg (< 1 μg/dm2) FTOH into food has
been calculated as the sum of 6:2 FTOH, 8:2 FTOH,
and 10:2 FTOH in an acetone extract of treated paper
under the assumption of complete migration [15,33].
Powley et al. [34], using liquid chromatography coupled
with tandem mass spectrometry were unable to detect a
migration of PFOA from PFTE-coated cooking utensils
(LOD 0.1 ng/cm2).
Stahl et al. Environmental Sciences Europe 2011, 23:38
http://www.enveurope.com/content/23/1/38
Page 5 of 52
Begley et al. [35] showed that nonstick cooking uten-
sils contribute less to PFC exposure to food than coated
papers or cardboard boxes. Residual amounts of PFOA
in the range of a few micrograms per kilogram or nano-
grams per gram were all that could be detected in PTFE
cooking utensils. Of the total amount of PFOA in a
PTFE strip, 17% (30 ng/dm2) migrated into the food
simulant heated to 175°C for 2 h. In contrast, some
paper and cardboard surface coatings contained large
amounts of PFCs. For example, microwave popcorn
bags were found to contain 3 to 4 mg/kg (11 μg/dm2).
After heating, the PFOA concentration in the popcorn
itself was about 300 μg/kg. PFOA migrated into the oil
that coated the popcorn. Migration was enhanced by a
temperature of 200°C [35].
Sinclair et al. [36] examined the emission of residual
PFOA and FTOH from nonstick cooking utensils and
microwave popcorn bags upon heating to normal cook-
ing temperatures (179°C to 233°C surface temperature).
Heating nonstick frying pans released 7 ng to 337 ng
(0.11 to 5.03 ng/dm2) PFOA in the gas phase. Further-
more, concentrations of 6:2 FTOH and 8:2 FTOH of
< 0.15 to 2.04 ng/dm2 and 0.42 to 6.25 ng/dm2 were
detected. Repeated use of some frying pans was
observed to result in a reduction in PFOA concentra-
tions emitted in the gas phase. However, this was not
the case for all frying pans from all of the manufacturers
tested. In addition, 5 to 34 ng PFOA and 223 ± 37 ng
(6:2 FTOH) as well as 258 ± 36 ng (8:2 FTOH) per bag
were detected in the emitted vapor from microwave
popcorn bags [36].
Tittlemier et al. [37], in the Canadian Total Diet
Study, examined food samples between 1992 and 2004
for contamination with N-ethylperfluorooctyl sulfona-
mide [N-EtFOSA], FOSA, N,N-diethyl-perfluorooctane-
sulfonamide, N-methylperfluorooctyl sulfonamide, and
N,N-dimethyl-perfluorooctanesulfonamide. FOSA, in ng/
kg and a few μg/kg amounts, was detected in all food
products tested (pastries, candies, milk products, eggs,
fast-food products, fish, meat, and convenience foods).
The highest concentrations (maximum 27.3 μg/kg) were
found in fast-food products (French fries, sandwiches,
pizza), which are foods that are commonly packaged in
grease-proof paper. Dietary FOSA uptake in Canada was
Table 6 PFOS and/or PFOA concentrations of various foods (μg/kg)








Grain products PFOS n.r. < LOQ < 0.069 < 10 ± < 2
PFOA n.r. < LOQ to 0.5 < 0.080 < 5 ± < 1
Milk PFOS n.r. < LOQ to 0.5 < 0.014 < 0.5 ± < 0.1
PFOA n.r. < LOQ 0.056 < 0.5 ± < 0.1
Milk products PFOS n.r. 0.04 to 0.08 0.121 < 5 ± < 1
PFOA n.r. < LOQ < 0.040 < 5 ± < 1
Eggs PFOS 0.51 0.08 to 0.5 0.082 1 ± 0.2
PFOA 1.6 < LOQ < 0.055 < 1 ± < 0.2
Fats and oils PFOS n.r. < LOQ < 0.099 < 0.5 ± < 0.1
PFOA n.r. < LOQ < 0.247 < 1 ± < 0.2
Fish PFOS 9 to 67 0.2 to 60 0.407 < 5 ± < 1
PFOA 1.3 to 2 < LOQ to 2 < 0.065a < 3 ± < 0.6
Meat PFOS n.d. 0.03 to 0.5 0.045 < 10 ± < 2
PFOA n.d. < LOQ to 1 < 0.053b < 2 ± < 0.4
Offal from game PFOS 172 n.r. n.r. n.r.
PFOA 4.3 to 6.9 n.r. n.r. n.r.
Fruits PFOS n.r. 0 < 0.017 < 2 ± < 0.4
PFOA n.r. < LOQ to 0.3 < 0.036 < 5 ± < 1
Vegetables PFOS n.d. < LOQ to 0.5 0.022 < 3 ± < 0.6
PFOA n.d. < LOQ to 0.3 < 0.027 < 10 ± < 2
Potatoes PFOS 1.2 4 to 8 n.r. 10 ± 2
PFOA n.d. 0.4 to 2 n.r. 1 ± 0.2
Candies/Honey/Sugar PFOS n.d. 0.8 to 1.2 n.r. 1 ± 0.2
PFOA 0.5 < LOQ n.r. < 1 ± < 0.2
Tap water PFOS 0.004 to 0.008 < LOQ to 0.01 n.r. n.r.
PFOA 0.02 to 0.13 < LOQ to 0.2 n.r. n.r.
aFish; bpork; n.r., not reported; n.d., not detected; LOQ, limit of quantification.
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estimated to be 73 ng/person/day. The N-EtFOSA con-
centrations in the samples seem to drop throughout the
time period of sampling. This is possibly the result of
fact that manufacturing of perfluoro octylsulfonyl com-
pounds was discontinued [37,38].
In studies of packaged food products carried out by
Ericson Jogsten et al. [39], PFHxS, PFOS, PFHxA, and
PFOA were detected at levels above the LOD (PFHxS
0.001 μg/kg, PFOS 0.008 μg/kg, PFHxA 0.001 μg/kg,
PFOA 0.063 μg/kg) in at least one mixed-food sample.
Among the packaged foods tested were goose liver paté,
deep-fried chicken nuggets, frankfurters, marinated sal-
mon, and head lettuce [39].
Similar to the results of Begley et al. [35], the US Food
and Drug Administration [FDA] named coated paper as
the largest possible source of fluorochemicals. According
to the FDA, nonstick frying pans are, by comparison, an
insignificant source of PFCs [15]. In the ninth list of
substances for food contact materials, the EFSA Panel
on food additives, flavourings, processing aids and mate-
rials in contact with food [AFC] recommends limiting
the use of ammonium perfluorooctanoate [APFO] for
articles with repeated use to those on which the coating
is baked at a high temperature. According to the analyti-
cal data, APFO, as auxiliary material in the production
of PTFE, could not be detected at levels above the LOD
of 20 μg/kg in the finished product. In the worst case,
the AFC determined an APFO migration of 17 μg/kg
food [15]. As a result of advances in food technology,
contamination of foodstuffs during manufacturing,
packaging, or cooking only plays a minor role in the
total exposure of humans to PFCs [15].
The German Federal Environment Agency has rated
the uptake of PFCs through the use of nonstick pots
and pans as low. The available data are, however, not
yet adequate for a reliable assessment of PFC exposure
through food contact materials [4].
Several studies point out the possibility of underesti-
mation of PFC exposure through food contact materials.
Mixtures of perfluorooctanesulfonamide esters are often
used in the manufacture of water- and greaseproof
papers and cardboards. These perfluorooctylsulfonyl
compounds have yet to be studied. They may remain as
residues in the coatings and migrate into the food.
D’Eon and Mabury [40] examined the formation of
PFCA through the biotransformation of polyfluoroalkyl
phosphate surfactants [PAPS]. The authors showed that,
in spite of their large molecular size, these substances
are bioavailable and that PFOA and other PFCs may be
formed by their biotransformation. PAPS can probably
be degraded by dephosphorylating enzymes in organ-
isms because of the phosphate-ester bond between the
fluorinated part and the acidic head group. However, it
should be noted that the rats in this study were fed high
oral doses of 200 mg/kg PAPS. Renner raises concerns
of the fact that PAPS may migrate much more effec-
tively into emulsions such as butter, margarine, or
lecithin additives than into food simulants such as oil or
water [40,41].
The fact that studies using conventional food simu-
lants do not accurately reflect the actual migration of
fluorochemicals into food was confirmed by Begley et al.
[42]. They recommend an emulsion containing oil as
simulant for greasy food products. The authors mea-
sured the migration of three PAPS from the paper pack-
ing material, finding 3.2 mg/kg in popcorn after
preparation and 0.1 mg/kg in packaged butter after a
40-day storage by 4°C [42].
Lv et al. [43] determined the contents of PFOA and
PFOS in packing materials and textiles by means of
liquid extraction under pressure and subsequent gas
chromatography coupled with mass spectroscopy analy-
sis. PFOA concentrations of 17.5 to 45.9 μg/kg and
PFOS concentrations of 17.5 to 45.9 μg/kg were found
in the packing materials and textiles tested [43].
Given the present state of knowledge, it is not possible
to say whether the use of nonstick-coated cooking uten-
sils or packaging materials with PFC-based coating lead
to a significant increase in dietary internal PFC contami-
nation of humans.
Additional potential pathways of exposure leading to
internal polyfluorinated compound contamination of
humans
PFCs may also enter the body by ingestion of dust and
dirt particles and by contact with products that have
been treated with substances that contain PFCs or its
precursor compounds [9,44]. These may include carpets,
upholstered furniture, or textiles. These routes of entry
may be of particular importance in regard to children
because contact can occur indirectly by hand-to-mouth
transfer or directly if an infant sucks on the product.
Another route that must be considered is inhalation of
PFCs in indoor or outdoor air [10,45,46] as well as the
inhalation of waterproofing sprays. Dermal exposure
may also occur by skin contact with PFC-treated pro-
ducts [17].
Exposure via non-food personal items
An estimate of exposure via non-food products is diffi-
cult because of the large number of possible applications
of PFCs such as for jackets, trousers, shoes, carpets,
upholstered furniture, and as cleaning agents. In addi-
tion, only data are available concerning possible PFCs
exposure via non-food products. In order to make an
estimation of exposure, research groups such as Wash-
burn et al. [47] have resorted to the use of models.
In this study, the concentrations of deprotonated
PFOA [PFO] (the anion of PFOA) were determined by
Stahl et al. Environmental Sciences Europe 2011, 23:38
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extraction tests and information about the composition
of the products. Values from the study by Washburn et
al. [47] are shown in Table 7.
Age-specific behavior was taken into account in order
to assess the PFO exposure of consumers through con-
tact with these products. A one-compartment model
was chosen to determine the contribution of PFC-trea-
ted non-food products to the concentration of PFO in
serum, and a dermal absorption coefficient of 1.0 × 10-5
per hour was adopted. The values obtained are hypothe-
tical and are categorized as more typical exposure
[MTE] or reasonable maximum exposure [RME] scenar-
ios. An assumable daily total PFOA exposure via non-
food articles for adults was estimated at 0.09 ng/kg BW
(MTE). The maximum uptake of PFOA was estimated
at 3.1 ng/kg BW (RME). According to this assessment,
the exposure would drop by one or two orders of mag-
nitude upon reaching adulthood because of the low fre-
quency of hand-to-mouth transfer [15,47].
Exposure via indoor and outdoor air
Based on studies in Japan [48] and Canada [49], the
EFSA determined the lifetime average daily dose
[LADD] via ingestion, inhalation, and skin contact with
contaminated house dust in interior rooms. The corre-
sponding data are presented in Table 8. These calcula-
tions by the EFSA are based on mean PFC
concentrations of 0.440 ng PFOS/kg and 0.380 ng
PFOA/kg in house dust. The exposure to PFOS and
PFOA through inhalation was estimated at 0.022 ng/m3
and 0.019 ng/m3, respectively [15].
In a recent study by Kato et al. [50], 39 samples of
house dust that had been collected in diverse countries
worldwide in 2004 were tested for concentrations of 17
PFCs. Six of the compounds were detected in 70% of
the samples tested. The highest mean values measured
were for PFOS, PFBS, PFHxS, perfluorooctanesulfona-
mide ethanol [FOSE], 2-(N-ethyl-perfluorooctanesulfo-
namido) acetic acid (Et-PFOSA-AcOH), and 2-(N-
Methyl-perfluorooctanesulfonamide) ethanol [Me-FOSE]
[50]. The values are shown in Table 9.
Data have been published on the inhalation exposure
to PFOS and PFOA for Norway, the UK, Japan, and
North America. As a result of the large variability of the
PFC concentrations in outdoor air, the EFSA calculated
LADD values for ‘high’ and for ‘low’ PFC exposures via
inhalation of outdoor air. The PFOS and PFOA concen-
trations of air and dust that were used as basis for cal-
culation, as well as the LADD values, are shown in
Table 10.
Consequently, the uptake of PFOS and/or PFOA from
outdoor air, even assuming a high concentration of
PFCs, amounts to less than 0.5% or 17%, respectively, of
the contamination via indoor air and, in comparison to
dietary uptake, would therefore appear to be negligible
[15].
Table 7 PFO concentrations in consumer articles (from Washburn et al. [47])
Product group Concentration according to
information on product composition
(mg PFO/L)
Calculated total concentration in the
end product (mg PFO/kg end
product)
Results of the extraction tests from








1 to 50 0.2 to 2 28 to 50 (n = 14)
Treated clothing < 1 to 40 < 0.02 to 1.4 < 0.01 to 12 (n = > 100)
Treated upholstered
furniture
< 1 < 0.034 0.4 to 4 (n = 3)
Treated home
textiles
< 1 to 40 < 0.02 to 1.4 not tested
Latex paint 50 to 150 0.02 to 0.08 not tested
Cleaning product 50 to 150 0.005 to 0.05 not tested
Table 8 PFOS and PFOA uptake via inside air (ng/kg BW/
day; from EFSA [15])
Exposure source PFOS uptake PFOA uptake
Ingestion of house dust 0.57 0.49
Skin contact with house dust 0.36 0.31
Inhalation of house dust 0.006 0.005
® LADDa 0.93 0.81
aLADD, lifetime average daily dose.
Table 9 PFC concentrations in 39 samples of house dust
(from Kato et al. [50])
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Fromme et al. [38] summarized human exposure to
PFCs via outdoor and indoor air in western countries. A
comparison of the various PFCs in outdoor air shows
that the levels of FOSE or FOSA, PFOS, and PFOA con-
centrations decrease according to the sequence city,
country, and outlying regions. Furthermore, there
appears to be a north-south gradient since the maxi-
mum 8:2 FTOH concentrations were 0.19 ng/m3 in the
northern hemisphere and 0.014 ng/m3 in the southern
hemisphere. In addition, it must be assumed that there
are seasonal variations in PFOS and PFOA concentra-
tions in outdoor air. Samples taken in the spring con-
tained higher concentrations of PFCs than samples from
the winter. [38].
Total exposure
The individual pathways of exposure according to EFSA
[15] and Fromme et al. [38] are summarized, and the
resulting total exposure to PFCs is calculated in Table
11. The calculated total exposure according to the data
of the EFSA [15] and Fromme et al. [38] are of the
same order of magnitude for PFOA. For PFOS, the total
exposure derived from the data of the EFSA [15] is sig-
nificantly higher than the result obtained using the data
from Fromme et al. [38]. This resulted from the higher
values for dietary exposure according to the EFSA [15].
According to this assessment, exposure via drinking
water and outdoor air appear to be insignificant, barring
special sources of contamination.
Fromme et al. [51] initiated a study, the Integrated
Exposure Assessment Survey [INES] in which PFC
concentrations in foods, indoor air, and house dust were
correlated with concentrations in blood. The blood con-
centrations of the 48 INES participants varied between
4.9 to 55.0 μg/L for PFOS and 2.7 to 19.1 μg/L for
PFOA. Further details have not yet been published since
the study is ongoing.
Zhang et al. [52] took a different approach. The daily
uptake, calculated from blood concentrations using a
one-compartment model, was found to agree closely
with the daily PFOS uptake via food and house dust
(0.74 vs. 1.19 ng/kg BW for men and 1.2 vs. 1.15 ng/kg
BW for women) [52].
Pre- and postnatal exposures
PFC exposure of the fetus (prenatal) and nursing infants
(postnatal) has also been shown in studies of mother-
child pairs.
Prenatal exposure
PFOS was detected in cord blood samples in studies
from Northern Canada, Germany, Japan, the USA,
Canada, and Denmark [37,53-57]. This also applies to
PFOA, with the exception of the Japanese study [54].
Thus, PFCs are considered to cross the placental barrier.
This was also shown in animal studies [58].
In the northern Canadian study, the mean PFOS- and
PFOA-cord blood concentrations in humans were 17
μg/L and 3.4 μg/L, respectively. In the other studies, the
values were from 3 to 7 μg/L for PFOS and 1.6 to 3.4
μg/L for PFOA. In the German study, PFOS concentra-
tions in cord blood were reported to be lower than the
mother’s blood by a factor of 0.6 (7.3 μg/L vs. 13 μg/L).
By contrast, however, the PFOA concentrations were a
factor of 1.26 higher in cord blood than in the mother’s
blood (3.4 μg/L vs. 2.6 μg/L) [53].
Inoue et al. [54] also compared PFOS concentrations
in the mother’s blood with the cord blood of the fetus.
The concentration in the maternal blood varied from
4.9 to 17.6 μg/L, whereas the cord blood concentration
had a PFOS level of 1.6 to 5.3 μg/L. A strong correlation
Table 10 PFOS and PFOA uptake via ingestion and
inhalation of outdoor air (from EFSA [15])
Outdoor air contamination Low uptake High uptake
PFOS PFOA PFOS PFOA
In dust (μg/kg) 30 400 100 4000
In air (ng/m3) 0.001 0.003 0.01 0.3
® LADD (ng/kg BW/day) 0.00069 0.0063 0.0041 0.14
Table 11 Estimate of total PFC uptake for adults (ng/kg BW/day)
Source of
contamination
EFSA [15] Fromme et al.
[38]
EFSA [15] Fromme et al.
[38]
Fromme et al. [38] Fromme et al. [38]
PFOS PFOS PFOA PFOA FTOH FOSE/FOSA
Diet 60 to 200 1.5 to 4.48 2 to 6 2.82 to 11.5 n.r. 0.217-6.87
Fish 45 to 58 n.r. 1.7 to 2.1 n.r. n.r. n.r.
Drinking water 0.24 0.023 to 0.130 0.31 0.022 to 0.087 n.r. n.r.
Indoor air + house
dust
0.93 0.0047 + 0.032 to
4.22
0.81 0.0009 + 0.016 to
1.03
0.038 to 0.105 + 0.103 to
1.02
0.460 to 2.05 + 0.983 to
2.03
Outdoor air 0.001 to
0.004
0.0001 to 0.001 0.006 to
0.14
0.001 to 0.012 0.003 0.001 to 0.012
Total uptake 60.9 to 200 1.56 to 8.84 2.82 to
6.95
2.86 to 12.6 0.144 to 1.13 1.66 to 10.9
n.r, Not reported.
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was found between the PFOS concentration in the
mother’s blood and in cord blood (r2 = 0.876). In this
study, PFOA was only found in the mother’s blood [54].
Monroy et al. [56] also made comparative measure-
ments of PFC concentrations in mother’s blood (n =
101) in the 24th to 28th week of gestation and at the
time of birth as well as in cord blood (n = 105). These
authors established higher PFOS concentrations in the
mother’s blood during pregnancy than at the time of
birth. PFOS concentrations in cord blood were lower
than those in the mother’s blood samples.
Fei et al. [57] also examined PFOS and PFOA concen-
trations in the blood of women during the first trimester
(n = 1, 400) and during the second trimester (n = 200)
of pregnancy. They also analyzed cord blood (n = 50)
after birth. The values from these last two studies are
shown in Figure 1.
Postnatal exposure
The presence of PFOS and PFOA in human breast milk
was demonstrated in studies from Sweden [59] and
China [60], among others. The PFC concentrations mea-
sured in these studies were similar. In another study by
Völkel et al. [61], PFOS and PFOA concentrations were
also determined in 57 human milk samples from Ger-
many and 13 samples from Hungary. The PFOA concen-
trations measured in this study (0.201 to 0.46 μg/L) were
similar to those reported by So et al. [60] and Kärrman et
al. [59]. Only 11 PFOA values were greater than the LOD
of 0.2 μg/L. In the Swedish study, the same problem
emerged, whereby only one sample contained concentra-
tions greater than the blank level of 0.209 μg/L.
In 24 pooled samples of human milk (1, 237 individual
samples) obtained in the year 2007 from 12 provinces of
China, Liu et al. [62] measured PFOS concentrations of
0.049 μg/L (mean) and for PFOA, 0.035 μg/L. The con-
centrations of PFCs varied greatly between different geo-
graphic regions. High concentrations of PFOA were
measured in Shanghai (0.814 μg/L in rural areas and
0.616 μg/L in urban areas) [62].
PFOS and/or PFOA concentrations measured in
human milk samples by Kärrman et al. [59], So et al.
[60], Völkel et al. [61] and Liu et al. [62] are shown in
Table 12.
Using the data from the Swedish study, for example,
an infant who weighs 5 kg and drinks 800 mL human
milk per day would have a daily uptake of 0.048 to 0.38
μg PFOS and 0.17 to 0.39 μg PFOA [15]. If the data
from Shanghai are used, the infant would ingest more
PFOA (consumed volume = 742 mL/day, BW = 6 kg)
amounting to 0.088 μg/kg BW [62], thereby nearly
reaching the TDI of 0.1 μg/kg BW/day recommended





































PFOS PFOA Fei et al. 2007 Monroy et al. 2008 GW: Gestation week
birth
umbilical cord
Figure 1 PFOS and PFOA blood concentrations in maternal blood and in cord blood. (By Fei et al. [57]; Monroy et al. [56]).
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It can be seen in the study by Kärrman et al. [59] that
the mean PFOS concentration of 0.201 μg/L in human
milk is correlated with the serum PFOS concentration
of 20.7 μg/L (r2 = 0.7), reaching a level of about 1% of
the serum concentration. A similar and even stronger
correlation (r2 = 0.8) was also determined for PFHxS
(milk 0.085 μg/L, serum 4.7 μg/L). The total concentra-
tion of PFCs was 32 μg/L in serum and 0.34 μg/L in
milk. The authors calculated a PFC uptake of about 0.2
μg/day for infants. The PFOS and/or PFHxS concentra-
tions in human milk samples that had been obtained
between 1996 and 2004 showed little variation through-
out that time period, providing no evidence of a possible
temporal trend [59].
Tao et al. [63] analyzed PFC concentrations in human
milk samples from various Asian countries. The PFOS
concentration varied between 0.039 μg/L in India and
0.196 μg/L in Japan. The mean PFHxS concentrations
ranged from 0.006 μg/L (Malaysia) to 0.016 μg/L (Phi-
lippines). The mean PFOA concentration in Japan was
0.078 μg/L. In addition, the average PFC uptake of nur-
sing infants from seven Asian countries was compared
to the dietary uptake values from adults in Germany,
Canada, and Spain. The PFOS uptake of nursing infants
(11.8 ± 10.6 ng/kg BW/day) was 7 to 12 times higher,
and the PFOA uptake (9.6 ± 4.9 ng/kg BW/day) was 3
to 10 time higher than the dietary exposure of adults to
these substances [63].
Llorca et al. [64] also analyzed human milk samples
for PFC contamination. The milk samples, from donors
living in Barcelona, Spain, were all from at least 40 days
after birth. PFOS and perfluoro-7-methyloctanoic acid
were detected in 95% of all samples. Concentrations of
0.021 to 0.907 μg/L PFOA were measured in 8 out of
20 human milk samples. According to this study, infants
ingest 0.3 μg PFCs/day while nursing [64].
According to the results of these studies, nursing con-
tributes to PFC exposure of infants. The mechanism by
which these compounds pass from the mother’s blood
to the milk is not fully understood. Bonding to proteins
would appear likely [38,65].
PFC contaminations of infant formulas were examined
in two studies. Tao et al. [63] detected PFC concentra-
tions above the LOD in only a few casesa. Llorca et al.
[64] found six PFCs in all baby formulas of various
brands as well as in baby cereals. Elevated concentra-
tions (as high as 1.29 μg/kg) of perfluorodecanoic acid
[PFDA], PFOS, PFOA, and perfluor-7-methyloctanoic
acid were detected. Contamination of baby food is likely
the result of migration of the compounds from the
packaging or containers used during production [64].
Human internal contamination
Taves [66] and Shen and Taves [67] were the first to
show the presence of organic fluorides in human blood.
Until the 1990s, however, the presence of these com-
pounds was not considered of importance. Only since
1993 have PFC concentrations in the serum of exposed
workers been the subject of study. The PFOS concentra-
tions in the serum were found to be between 1, 000 and
2, 000 μg/L. Data on serum concentrations in the gen-
eral population have only been available since 1998.
These values were approximately 100 times lower than
in occupationally exposed workers [15,68,69].
The plasma to serum ratio for PFHxS, PFOS, and
PFOA is 1:1, independent of the concentration, whereas
the ratio of serum or plasma to whole blood was stated
to be 2:1. This indicates that the PFC concentration in
whole blood is only 50% of the concentration in plasma
and/or serum. The difference is the result of the distri-
bution volume of red blood cells in the samples since
fluorochemicals are neither found intracellularly nor
bound to the red blood cells [70].
Kannan et al. [71] examined 473 blood/serum/plasma
samples from people of various countries. Of the four
PFCs measured (PFOS, PFHxS, PFOA, FOSA), PFOS
was quantitatively the dominant component in blood.
The highest PFOS concentrations were detected in sam-
ples from the USA and Poland (> 30 μg/L). In Korea,
Belgium, Malaysia, Brazil, Italy, and Colombia, blood
PFOS concentrations were in the range of 3 to 29 μg/L.
The lowest PFOS concentrations were measured in sam-
ples from India (< 3 μg/L). In this study, the PFOA con-
centrations were lower than the values for PFOS, except
in India and Korea. The joint occurrence of the four
PFCs varied according to the country of origin of the
samples. This suggests differences in the exposure pat-
tern in the individual countries [71].
Kärrman et al. [72] measured plasma PFOS concentra-
tions from residents of Australia, Sweden, and the UK
Table 12 PFOS and PFOA concentrations (μg/L) of human breast milk
Substance Sweden China Germany
Kärrman et al. [59] So et al. [60] Liu et al. [62] Völkel et al. [61]




0.049 (median) 0.028 to 0.309 German samples
0.096 to 0.639 Hungarian samples
PFOA < 0.209 to 0.492 0.047 to 0.21
0.106 (arithmetic mean)
0.035 (median) 0.201 to 0.46
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with levels of 23.4 μg/L, 33.4 μg/L, and 14.2 μg/L,
respectively. Ericson et al. [73] determined average
values of 7.64 μg PFOS/L and 1.8 μg PFOA/L in blood
samples from the Spanish population [15].
Calafat et al. [74], within the framework of the
National Health and Nutrition Examination Surveys
[NHANES] from 1999 to 2000, also examined serum
samples from the US population for concentrations of
11 different PFCs. The group of 1, 562 participants in
the study was made up of male and female subjects,
three ethnic groups, and four age categories (12 to 19
years, 20 to 39 years, 40 to 59 years, 60 years and
older). Consequently, these data are representative of
the exposure of the US population to PFCs. PFOS,
PFOA, PFHxS, and FOSA were detected in all serum
samples [74]. The values are presented in Table 13.
Wilhelm et al. [75] took three biomonitoring studies
as a basis to arrive at a reference value for PFOA and
PFOS in the blood plasma of the general population in
Germany. Two studies were carried out in southern
Germany [76,77] and one in North Rhine Westphalia
[19]. Although these studies are not representative of
the general population of Germany, they present the
best basis for deriving a reference value for internal con-
tamination with PFOS and PFOA. Based on the 95th
percentile, the following reference values were sug-
gested: for PFOA, 10 μg/L for all groups and for PFOS,
10 μg/L for children of school age, 15 μg/L for adult
women, and 25 μg/L for men [75].
The mean PFOA concentration in the blood for the
European population is within the region of 4 to 20 μg/
L; their mean PFOS serum concentration is within the
range of 4 μg/L (Italy) and 55 μg/L (Poland). PFOS is
the quantitatively dominant component of PFCs in all of
the blood samples measured worldwide. In general,
PFOA concentrations in serum are lower than concen-
trations of PFOS [15].
Olsen et al. [69] determined the PFOS concentrations
in serum to be 6.1 to 58.3 μg/L and in human liver, 4.5-
57 μg/kg (n = 31). The mean liver to serum ratio for
PFOS concentration was 1.3:1. Liver to serum ratios
could not be established for PFOA, PFHxS, and FOSA
because 90% of the concentrations of these substances
were below the LODa [69].
Kärmann et al. [78] analyzed blood samples from 66
Swedish study participants. Concentrations of 12 PFCs
were determined (PFBS, PFHxS, PFOS, perfluorooctane-
sulfonamido acid, FOSA, PFHxA, PFOA, perfluoronona-
noic acid [PFNA], PFDA, perfluoroundecanoic acid
[PFUnA], perfluorododecanoic acid [PFDoA], perfluoro-
tetradecanoic acid [PFTDA]) along with the concentra-
tions of other ‘traditional’ persistent organic pollutants
[POPs]. The mean concentrations of PFCs in whole
blood were 20 to 50 times higher than the total concen-
trations of polychlorinated biphenyls [PCB] and p, p’-
dichlorodiphenyldichloroethylene. Similarly, the PFC
concentrations were 300 to 450 times greater than for
hexachlorbenzene and the sum of the six chlordanes
and the three polybrominated diphenyl ethers. However,
the PFCs and the POP that were measured behaved dif-
ferently in regard to their distribution in the body, mak-
ing an additional comparison of total body
contamination necessary. PFCs are mainly found in the
blood and the liver, whereas polychlorinated and poly-
brominated POPs are chiefly present in the fat tissue
and blood lipids. The reason for these differences
appears to be related to the different basic structures
and the binding behavior in blood of these substances
[40,79,80]. Whole blood contains about 0.5% blood
lipids, and thus represents only a small part of the total
body contamination of PCB for example. The total body
contamination was calculated using the proportionate
weights of the main distribution tissues. This analysis
showed a similar total body contamination for PFCs and
for the POP that had been analyzed to be about 1.6 mg
PFOS and 1.7 mg for PCB153, one of the most abun-
dant individual PCB congeners [72].
Gender and age-dependent differences
No correlation between the PFOS concentration and age
or gender were found in studies by Olsen et al. [69] on
US citizens or in the studies by Kannan et al. [71]. Data
of Calafat et al. [74,81] show significantly higher PFOS
and PFOA concentrations in men than in women; how-
ever, an age-related difference was not found. Harada et
al. [82] reported higher PFC serum concentrations in
Japanese men than in women, and in addition, they also
reported a rise in PFC serum concentrations in women
with increasing age so that by age 60, the concentrations
in women were comparable to those in men. The situa-
tion was similar for PFOA [82].
Kärrman et al. [83] determined a rise in PFOS serum
concentrations with increasing age. PFOS, PFOA, and
PFHxS concentrations in blood were also higher in men
than in women. Ericson et al. [73] confirmed higher
PFHxS and PFOA concentrations in blood of male sub-
jects. Concentrations were significantly different
between age groups 25 ± 5 years (18 participants) and
55 ± 5 years (30 participants) only for PFHxS and FOSA
Table 13 PFOS and PFOA serum concentrations (μg/L) of
the US population (from Calafat et al. [74])
Substance 10th Percentile 50th Percentile 95th Percentile
PFOS 15.1 30.2 75.6
PFOA 2.8 5.1 11.9
PFHxS 0.8 2.1 8.7
FOSA < 0.1 0.3 1.4
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(p < 0.05 and p < 0.001, respectively). The group of
younger participants (25 ± 5 years) presented higher
PFHxS values and lower FOSA values than did the older
participants [73].
Rylander et al. [84] also registered higher concentra-
tions of PFOS, PFOA, PFHxS, and PFHpS in male Nor-
wegian participants than in women. Here, also
increasing concentrations of PFOS, PFHxS, and PFHpS
were observed with increasing age.
A study of 245 blood samples of donors from China
showed that lower concentrations of PFOS were
detected in infants, young children, children, and adoles-
cents (2.52 to 5.55 μg/L) than in adults (8.07 μg/L), and
correlations of PFOS (r = 0.468) and PFHxS (r = 0.357)
with age were reported. In contrast, PFOA concentra-
tions in blood of the children and adolescents were
higher (1.23 to 2.42 μg/L) than in adults (1.01 μg/L),
showing a negative correlation with age (r = -0.344).
The composition of the PFC concentration profiles also
varied between age groups, suggesting different sources
of exposure. Gender specific differences in PFC concen-
tration could not be determined in any of the groups
[52].
Fromme et al. [77] carried out a study of PFC concen-
trations in blood of participants in Germany. Concentra-
tions of PFOA and PFOS were measured in 356 blood
plasma samples. The mean values of 10.9 μg/L PFOS
and 4.8 μg/L PFOA were determined for women. The
values for men were higher (13.7 μg/L PFOS and 5.7
μg/L PFOA). Higher blood PFC concentrations corre-
lated with increasing age in students; however, this cor-
relation was only statistically significant for female
students [77]. A second German study also confirmed
age as having an effect on PFC concentrations is plasma.
The age of men correlated positively with the plasma
concentrations of PFOS, PFOA, and PFHxS. In the case
of women, this was only true for PFOA [19]. In a US
American study, the mean PFOS and PFHxS concentra-
tions were significantly lower in participants who were
younger than 40 years than in the group over 40 years
[85]. The values from this study are shown in Table 14.
According to the EFSA [15], none of the studies
included show a clear difference in relationship to PFOS
and/or PFOA serum concentrations in relation to age or
gender of the participants. Fromme et al. [38] had come
to the conclusion, however, that the majority of the stu-
dies show gender-specific differences in serum concen-
trations of PFOS and PFOA. In regard to age
dependency, however, they agree with the EFSA [15]
that there is no significant correlation between age and
PFC blood concentrations although it must be assumed
that these compounds accumulate in the body over
time.
Since human biomonitoring studies showed higher
PFOS blood concentrations for men than for women,
Liu et al. [62,86,87] investigated the effect of pregnancy,
menstruation, and periodic exposure to PFOS concen-
tration in the blood of mice. The animals received 50
μg/L PFOS in their drinking water. Pregnancy or men-
struation led to lower PFOS concentrations in the
blood. Every additional individual exposure to PFOS
increased the concentration of the substance in blood.
Geographic and ethnic differences
Geographical differences have been detected in the
PFOS and PFOA concentrations in serum of blood
donors in diverse countries. Kannan et al. [71] reported
differences in the occurrence of PFOS and PFOA
among blood donors in nine different countries. Harada
et al. [82] detected differences in the PFOS and PFOA
serum concentrations for both genders in Japan. The
concentrations of PFOS and PFOA in blood measured
in Germany were lower than the values from a study in
the USA and Canada [77].
Fromme et al. [38] came to the conclusion that serum
concentrations of the US population are higher than
those of inhabitants of Europe, Asia, or Australia. The
same is true of PFHxS [38] (Table 15).
Concentrations of 29 μg/L PFOS, 3.9 μg/L PFOA, 0.5
μg/L PFHxS, 0.8 μg/L PFNA, and 1.1 μg/L PFHpS
(mean values) were detected in 95% of all blood samples
from Norwegians [84]. In another Norwegian study of
315 women, concentrations of 20 μg/L PFOS, 4.4 μg/L
PFOA, 1.0 μg/L PFHxS, and 0.81 μg/L PFNA were
found in 90% of the plasma samples [88].
Kärrman et al. [83] did not find a difference in PFC
serum concentrations for participants from rural or
urban regions of Australia. Mean values for PFOS (20.8
μg/L), PFOA (7.6 μg/L), and PFHxS (6.2 μg/L) measured
in this study were similar to the values determined for
Table 14 PFOS, PFOA, and PFHxS concentrations in blood
(μg/L) according to age group
Substance < 40 years 40 to 60 years > 60 years
PFOS 24.8/33.3 31.7/33.6 35.3/35.1
PFOA 2.2/5.3 2.4/5.5 2.4/6.0
PFHxS 0.7/1.8 1.9/2.5 2.2/3.0
Values from 1974/1989 of Olsen et al. [85].
Table 15 Serum and plasma PFC concentrations (μg/L)
according to geographical origin of participants
Substance US population EU population Asian population
PFOS 656 1 to 116 n.r.
PFOA 88 0.5 to 40 n.r.
PFHxS < 0.4 to 712 < 0.4 to 40 0.1 to 20.9
Adapted from Fromme et al. [38]; n.r., not reported.
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serum concentrations in Europe and Asia, or higher, but
lower than in the USA.
In an African study, concentrations of 1.6 μg/L PFOS,
1.3 μg/L PFOA, and 0.5 μg/L PFHxS were measured in
the blood of mothers who were tested. Fifty eight per-
cent of the PFOS molecules present were in the linear
form. The highest PFC concentrations were detected in
the blood of people from urban and semi-urban regions,
which are areas with the highest quality of living condi-
tions [89].
Hemat et al. [90] determined a lower internal PFC
contamination of people in Afghanistan. PFOS concen-
trations of 0.21 to 11.8 μg/L were detected in blood, and
PFOA and PFHxS concentrations were below the LOD
of 0.5 μg/L. In drinking water, as well, PFOA or PFOS
concentrations were not detected at levels above the
LOD (0.03 and 0.015 μg/L). The studies cited here are
shown in Figure 2.
The study of Kannan et al. [71] in which samples were
obtained from nine different countries showed differ-
ences in levels of PFOS in relation to the country of the
donors. The US study [91] showed that non-Hispanic
whites had statistically significantly higher concentra-
tions of PFOS than both non-Hispanic blacks and Mexi-
can Americans; Mexican Americans had statistically
significantly lower concentrations than non-Hispanic
blacks. Genetic variability, diet, lifestyle, or a combina-
tion of all these factors may contribute to the different
patterns of human exposure to PFOS observed among
the population groups [15].
Dietary influences
A Swedish study in which samples of blood from 108
women were analyzed showed a correlation between
increased consumption of predatory fish (pike, perch,
zander) and PFOS concentration in the blood. This cor-
relation could not, however, be shown for total fish con-
sumption or for other groups of foodstuffs ([92] cited in
EFSA [15]). A Polish study established a correlation
between increased fish consumption and the highest
serum concentrations measured in 45 test candidates for
10 fluorochemicals (including PFOS and PFOA) [93].
In a study of 60 participants in Norway, Rylander et
al.[84] determined significantly lower concentrations of
PFOS and PFOA in the blood of candidates who stated
that they had consumed 150 g of vegetables and fruits
per week over the past year. In contrast, an increase
consumption of oily fish (150 g/week) led to signifi-
cantly higher concentrations of these substances in the
blood.
In another study, Rylander et al. [88] examined blood
from 315 Norwegian women between the ages of 48






































































Figure 2 PFC blood concentrations (μg/L) by country.
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amounts of fish had higher PFOS, PFNA, and PFHxS
concentrations in their blood than did younger women
with larger households and a more western diet of rice,
pasta, water, white and red meat, chocolate, snacks, and
pastry. No specific cluster of foods could be correlated
with higher PFOA blood concentrations [88].
Time trends
A study of 178 US serum samples shows an increase in
PFOS and PFOA concentrations between 1974 and
1989. The mean values of serum concentrations of
PFOS, PFOA, and PFHxS from 1974 and 1989 are
shown in Table 16. Serum samples collected in 2001 did
not show any further increase in PFC concentrations
[69,85].
A Japanese study established an increase in PFOS and
PFOA concentrations in serum samples over the last 25
years. PFOS concentrations increased by a factor of 3,
and PFOA concentrations by as much as a factor of 14
[82].
A continual increase in PFOA and PFOS over time
was also shown in a Chinese study in which serum sam-
ples from 1987, 1990, 1999, and 2002 were analyzed
[94]. The changes in serum concentrations over time as
shown in this study are presented in Figure 3.
On the other hand, another study showed the decline
of serum concentrations of PFOS by 32%, of PFOA by
25%, and of PFHxS by 10% (data from the NHANES
from 1999 to 2000). These changes can probably be
attributed to the change in production of PFOS and per-
fluorooctane sulfonylfluoride compounds. The PFNA
concentrations increased by 100% [95]. These values are
also shown in Table 16. The concentrations listed by
Olsen [69,85] are mean values, while those from Calafat
et al. [95] are geometric mean values, making a compar-
ison of the results difficult or impossible.
Studies from the Sauerland region of Germany show
constant PFOS and PFOA concentrations between 1997
and 2004; however, the plasma concentrations of PFHxS
have risen continuously since 1977 [21].
Differences dependent upon the isomery of the compounds
Studies have shown that the linear form of PFOS [L-
PFOS] is more plentiful than the branched isomers in
the human serum and plasma samples. L-PFOS was
seen to account for 58% to 70% of the total PFOS in
samples from Australia, 68% from Sweden, and 59%
from the UK. The disparities are presumably the result
of different sources of exposure in the various countries.
For example, a standard PFOS product produced by
electrochemical fluoridation [ECF] consists of 76% to
79% L-PFOS [72].
A study by De Silva and Mabury [96] showed that
98% of the PFOA in the serum of the participants was
linear PFOA [L-PFOA], so only 2% was present in the
branched form. The same is true of PFNA and PFUnA.
A standard PFOA product produced by ECF consists of
80% L-PFOA. The high proportion of L-PFOA in serum
can probably be attributed to the exposure and metabo-
lism of FTOH and alkanes [38].
Toxicology of perfluorinated compounds
Toxicokinetics of perfluorinated compounds
Uptake
Data from animal experiments show that PFC uptake
can occur by oral, inhalation, or dermal exposure
[97-102].
Oral uptake of PFOS and PFOA results in rapid and
almost complete assimilation. Ninety five percent of the
radioactively labeled PFOS dose (4.3 mg/kg BW) and
93% of the labeled PFOA-dose (11 mg/kg BW) were
resorbed by male rats within 24 h. The authors found
5% and 7% of the total radioactivity in feces and in the
digestive tract and concluded that the remainder is the
resorbed portion. These resorption data are from Gib-
son and Johnson [97] and were determined using 14C-
labeled PFOS and PFOA [17].
After 10 inhalations of 84 mg/m3 APFO, a mean con-
centration of 108 mg/L was measured in the blood of
male rats. The APFO blood concentration declined to
0.84 mg/L 84 days after the treatment [100].
Uptake via dermal exposition appears to be somewhat
weaker [101]. A study by Kennedy [99] showed a dose-
dependent increase in blood concentration of organo-
fluoro compounds in rats after dermal application of
APFO. The subchronic dermal treatment with 2, 000
mg APFO/kg resulted in blood concentrations of 118
mg/L.
In rats, an uptake of 8:2 FTOH via the skin was rela-
tively low. After 6 h of exposure, 37% of the substance
evaporated or was removed by washing. The evaporated
portion was trapped by a device attached to the skin
and was consequently analyzed. The treated area of skin
was washed with a soap-ethanol mixture, and the 8:2
FTOH concentration in the solvent was measured. In
these experiments, a single 8:2 FTOH dose of 125 mg/
kgc in 0.5% methyl cellulose was applied. The 8:2 FTOH
was labeled with 14C (3-14C 8:2 FTOH) and applied to
the shaved area of skin (10 μL/cm2) [102].
Distribution
PFOS and PFOA are weakly lipophilic, very water solu-
ble, and bind preferentially to proteins. The principle
Table 16 PFC concentration in blood (μg/L) by year
Substance Olsen et al. [69,85] Calafat et al. [95]
1974 1989 2001 1999 to 2000 2003 to 2004
PFOS 29.5 34.7 35.8 30.4 20.7
PFOA 2.3 5.6 4.7 5.2 3.9
PFHxS 1.6 2.4 1.5 2.1 1.9
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binding partner is albumin [61,103]; however, it also
binds to b-lipoproteins or fatty acid binding proteins in
the liver [L-FABP] [104].
Approximately 90% to 99% of the perfluoridated car-
boxylic acids in the blood are bound to serum albumin
[103,105]. The chain length and the functional group of
the PFCs have an influence on the preferential binding
site and binding affinity [80]. PFCs have the same bind-
ing site and a similar affinity to serum albumin as fatty
acids [80].
Qin et al. [106] used spectrometry to determine the
influence of the length of the carbon chain of perfluori-
nated carboxylic acids on the binding to bovine serum
albumin. They determined that the binding strength
increased with the increasing chain length of the per-
fluorinated compound. The changes in enthalpy and
entropy indicate that Van-der-Waals’ forces and hydro-
gen bonds are the dominant intermolecular forces [106].
Bischel et al. [79] also confirmed the high affinity inter-
actions between perfluorinated compounds and serum
albumin, in particular at low molar ratios. PFOS and
PFOA are primarily extracellular and accumulate pri-
marily in the liver, blood serum, and kidneys. Small
amounts of the substances are found in other tissues as
well. According to studies by Austin et al. [107] and
Seacat et al. [108], the liver to serum ratio for PFOS is
about 2.5. PFOS and PFOA were also found primarily in
the liver and kidneys of chickens [109] and Han et al.
[110] found an active uptake mechanism for PFO (the
anion of PFOA) in rat hepatocytes.
In addition, differences in distribution patterns may be
dose dependent. In experiments with rats, Kudo et al.
[111] found that 2 h after a single intravenous injection
of low-dosage PFOA (0.041 mg/kg BW), a larger propor-
tion of the substance is found in the liver (52%) than with
a higher dosage (27% for a dosage of 16.56 mg/kg BW).
Apparently, PFOA is distributed to the blood or other tis-
sues as soon as the level in the liver reaches 4 mg/kg. The
study does not provide an immediate explanation of
these results; however, a dose-dependent difference in
intracellular distribution between the membrane fraction
and the cytosol was observed for the two different
dosages of 0.041 mg/kg BW and 4 mg/kg BW. Injection
of the higher dosage resulted in PFOA primarily in the
cytosolic fraction. If the liver concentration remained
under 4 mg/kg, PFOA was found almost completely in
the membrane fraction with a remainder of 3% in the
cytosol. Kudo et al. [111] concluded that this indicates a
preferred bond of PFOA to membrane components that
are not unlimitedly available. As a consequence, higher
dosages of PFOA are distributed in the blood or other
tissues. Elimination via the bile rose with higher doses
were administered, suggesting transport of unbound
PFOA from the cytosolic fraction of the cell to the bile. A
biliary elimination rate of 0.07 mL/hr/kg BW was deter-
minedd. The rate of elimination rose in a dose-dependent
manner; however, the differences of the rates between
the administered doses were not significant [111].
Tan et al. [112] discovered differences in distribution

































Figure 3 PFOA and PFOS serum concentrations over time in China. (By Jin et al. [94]).
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species (rat or monkey), and gender. PFOS, probably
because of its higher liver to blood distribution coeffi-
cient, seemed to remain in the tissue longer than PFOA.
The maximal transport capacity of renal resorption in
monkeys was 1, 500 times greater than that of rats, and
the clearance of renal filtrate in the central compart-
ment was about 10 times greater. Male rats showed a
slower renal elimination of PFOA than female animals;
however, low PFOA concentrations (< 0.1 μg/mL) were
eliminated at a similarly slow rate by females [112].
In addition, Liu et al. [113] studied age-dependent dif-
ferences in the toxicokinetics of PFOS in mice. The con-
centrations and distribution ratios of PFOS in the blood,
brain, and liver of mice after a single subcutaneous
application of 50 mg PFOS/kg BW differed significantly
between the individual postnatal developmental stages.
With increasing age, the differences became more evi-
dent. Gender-specific differences were greater in older
mice. A study demonstrated the following distribution
pattern of FTOH:
Four to seven percent of the 14C-labeled 8:2 FTOH
was recovered in the tissue of rats 7 days after oral
applications (125 mg/kg), principally in the fat, liver,
thyroid, and adrenal tissues [102]. PFCs are also distrib-
uted in the milk and via the placenta, as described in
the ‘Pre- and postnatal exposures’ section.
PFOS could also be detected in the livers of rat fetuses
[114]. Additionally, on the basis of studies of rats, it was
possible to estimate that the PFOA plasma concentra-
tion of the fetus amounts to half the steady state con-
centration in the plasma of the mother animal. In the
transition of PFOA to the milk of the mother animal,
the steady state concentration in the milk was 1/10
lower than the level in plasma ([58] cited in EFSA
[15,115]). Peng et al. [116] determined that the ratio of
concentrations in the eggs of sturgeons to the concen-
tration in the liver of the mother sturgeon was 0.79 for
PFOA and 5.5 for perfluorotridecanoic acid.
Contamination with PFOA may have also resulted
from corresponding precursor substances. It has, for
example, been demonstrated that PFOA can be formed
from FTOH [31,32]. Following a single dose of 30 mg/
kg BW 8:2 FTOH on the eighth gestational day [GD]
(GD 8) in mice, the PFOA concentrations in the fetus
rose from 45 ± 9 μg/kg (GD 10) to 140 ± 32 μg/kg
(GD 18). Furthermore, PFNA was also detected at a
concentration of 31 ± 4 μg/kg (GD 18). For the mice
that were not contaminated with 8:2 FTOH in utero,
but rather through nursing, concentrations of 57 ± 11
μg PFOA/L were detected on the third and 58 ± 3 μg
PFOA/L on the 15th day after birth. This indicates
that the progeny became contaminated with PFOA by
nursing from the mother animal that had been
exposed to FTOH [117].
Metabolism
As far as it is known, PFOS and PFOA are not metabo-
lized in mammals. Thus, PFOA is not subject to
defluorination nor to phase-II metabolism of biotrans-
formation [101]. According to Fromme et al. [2], only
FTOH comes into question regarding metabolism.
For example, Fasano et al. [102] could detect glucuro-
nide and glutathione conjugates in the bile as well as
perfluorooctanoate and perfluorhexanoate in excrements
and in the plasma of male and female rats that had
received a single oral dose of 5 and 125 mg/kg 14C-
labeled 8:2 FTOH. This implies that FTOH is metabo-
lized and that a removal of CF2 groups takes place.
Other studies have also shown possible formation of
PFCA from FTOH [31,32,117]. It is generally assumed
that oxidation of the alcohol group takes place to form
fluorotelomer aldehyde, followed by oxidation to satu-
rated fluorotelomer compounds (fluorotelomer saturated
carboxylate [FTCA]). Butt et al. [118] examined in
greater detail the biotransformation pathway for 8:2
FTOH in rainbow trout, in particular, from the meta-
bolic intermediates 8:2 FTOH unsaturated carboxylate
[FTUCA] and 7:3 FTOH saturated carboxylate [FTCA].
The authors administered these intermediates as well as
8:2 FTCA to the trout for 7 days and then identified the
compound in the blood and liver for a further 10 days.
Exposure to 7:3 FTCA resulted in lower concentrations
of 7:3 FTUCA and perfluorohepatanoate (PFHpA) and
did not result in an accumulation of PFOA. Further-
more, 8:2 FTCA and 8:2 FTUCA were generated. PFOA
was formed when 8:2 FTCA and 8:2 FTUCA were admi-
nistered. These results suggest a b-oxidation beginning
with 8:2 FTUCA to 7:3 keto acid and 7:2 ketone for the
PFOA formation [118].
The emerging metabolic products are often more toxic
than the original substance itself. This was also shown
for FTOH in a study by Martin et al. [119]. In tests in
which isolated rat hepatocytes were incubated with
FTOH of various chain lengths, the shortest (4:2 FTOH)
and longest (8:2 FTOH) lengths showed a greater toxi-
city, in terms of the LC50 than did, e.g., 6:2 FTOH.
Treatment with 8:2 FTOH led to a decline in glu-
tathione [GSH] levels and an increase in protein carbo-
nylation and lipid peroxidation. The addition of
aminobenzotriazol, an inhibitor of cytochrome P450,
diminished the cytotoxicity of all tested FTOH and
decreased protein carbonylation and lipid peroxidation
of 8:2 FTOH. Preincubating the hepatocytes with hydra-
lazine or aminoguanidine (a carbonyl trap with nucleo-
philic amino groups that form adducts with aldehydes)
also reduced the cytotoxicity of 8:2 FTOH. Likewise, a
GSH-reactive a/b-unsaturated acid which is a result
from the metabolism proved more toxic than the corre-
sponding FTOH compound. It can be concluded from
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this that the toxicity of FTOH is the result of electro-
phonic aldehydes or acids, GSH decrease, and protein
carbonylation [119].
Excretion
Since PFOS and PFOA cannot be metabolized by mam-
mals, excretion is the only means by which the toxic
activity of these compounds can be eliminated once
they have been taken up by the body [17].
Measurements of PFC concentrations in urine and
feces yielded an elimination half-life of more than 90
days for PFOS in rats. The half-life of PFOA is markedly
shorter and exhibits gender-dependent differences, 2 to
4 h for female rats and 4 to 6 days for male rats [115].
Because of albumin binding of a large portion of PFCs
in the blood, the glomerular filtration rate is low. How-
ever, an active excretory mechanism via transport pro-
teins has been described in rats. This so-called organic
anion transporter [OAT] (OATs 2 and 3) enables the
uptake of PFOA from the blood by the proximal tubule
cells in the kidneys [120]. The expression of OAT 2 and
3 in the kidneys correlates with the excretion of PFOA
by rats and is presumably regulated by sex hormones.
This may explain why female rats have excreted 91% of
the applied dose of 14C-labeled PFOA after 24 h via
urine, while only 6% of the administered 14C-labeled
PFOA can be detected in the urine of male rats. An
active excretory mechanism has not yet been described
for PFOS ([121] cited in EFSA [15]).
Weaver et al. [122] confirmed the involvement of the
basolateral OATs 1 and 3 in renal secretion of C7-C9
PFCA in rats. On the other hand, the apical organic
anion transport polypeptide [OATP] 1a1 contributes to
the reabsorption of C8-C10 PFCA in the proximal
tubule cells of the rat, with the highest affinity to C9
and C10. The OATP 1a1 expression is heightened in
the kidneys of male rats and might therefore also help
explain the gender-specific differences in renal PFCA
excretion.
Experiments by Johnson et al. [123] show the presence
of an enterohepatic circulation of PFCs. Increased fecal
excretion of 14C-labeled PFOA and PFOS in rats was
observed after multi-day administration cholestyramine
per os, accompanied by a concurrent reduction in con-
centrations of the substances in the liver and plasma.
Cholestyramine is an anion-exchange resin; it is not
resorbed and carries PFOA and PFOS to the intestines
to be excreted. The rates of excretion for PFOA and/or
PFOS in rats that had received APFO (13.3 mg/kg) or
the potassium salt of PFOS (3.4 mg/kg) intravenously
were increased by 9.8 times and 9.5 times, respectively,
after a 14- or 21-day administration of a 4% cholestyra-
mine mixture in their feed [123].
Cui et al. [124] examined PFOS and PFOA excretions
in male rats during a 28-day consecutive administration
of PFOS and PFOA. Urine was confirmed as the pri-
mary path of excretion of PFOS and PFOA in rats in
this study. In particular, PFOA excretion rates were
greater in urine than in feces. Within the first 24 h after
the start of oral application of PFOA or PFOS, 24.7% to
29.6% PFOA and 2.6% to 2.8% PFOS of the oral dosage
(5 and 20 mg/kg BW/day) were excreted in the urine
and feces. The rate of excretion over this period of time
increased with the increasing dosage. The higher rate of
elimination indicates a lower accumulation capacity.
The rapid, almost total uptake and relatively weak elimi-
nation of PFOA and PFOS facilitate the bioaccumula-
tion in the body [124].
In experiments on chickens, Yoo et al. [109] deter-
mined a rate of elimination for PFOA six times higher
than for PFOS. The authors administered 0.1 or 0.5 g/L
PFOA or 0.2 or 0.1 g/L PFOS to the 6-week-old male
chickens for 4 weeks. A 4-week excretion phase for
PFOA and PFOS followed. The data from the study can
be seen in Table 17[109].
In primates, the half-life of PFCs is longer than in
other experimental animals such as mice and rats. The
elimination half-life is 14 to 42 days in male or female
cynomolgus monkeys after oral and intravenous applica-
tions. The PFOA concentrations after a 4-week oral
application are shown in Table 18. Urine was the princi-
ple path of excretion for PFOA in monkeys [125].
In contrast, the half-life of PFOA in Japanese maca-
ques is notably shorter (2.7 to 5.6 days) ([101] as cited
by Harada et al. [126]). A half-life of 110 to 130 days
was determined for nonhuman primates after a single,
intravenous application [127].
The elimination half-time for PFOS in male cynomol-
gus monkeys was found to be about 200 days [128]. In
addition to species-specific differences, the structure of
the PFCs can also influence excretion.
Benskin et al. [129] administered a single dose of 500
μg/kg BW PFOS, PFOA, and PFNA or 30 μg/kg BW
PFHxS to seven male Sprague-Dawley rats. Urine, feces,
blood, and tissue samples were taken over the following
38 days, and PFC concentrations were determined by
high performance liquid chromatography coupled with
tandem mass spectroscopy. It was found that all PFC
branch-chained isomers had a lower half-time in the
blood than the corresponding linear isomers. The only
exception was the PFOS isomer that had an a-perfluoro
methyl chain (1m-PFOS). This was probably less readily
excreted than the linear isomer of PFOS due to spatial
shielding of the hydrophilic sulfonate moiety. The
authors therefore reasoned that the property of PFOS,
PFOA, PFNA and PFHxS chain branching, in general,
lowers the half-life in the blood and increases excretion
rates. However, different kinetic data may arise depend-
ing upon gender, dosage, and species [129].
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Part two of this study examined the same circum-
stances under the more realistic conditions of a sub-
chronic exposure. PFCs were mixed with the feed and
administered to male and female rats over a period of
12 weeks, followed by a 12-week excretion phase. The
feed contained 0.5 μg/g of the ECF products PFOA
(approximately 80% linear), PFOS (approximately 70%
linear), and PFNA (linear form and isopropyl-PFNA).
Blood samples that were collected during the exposure
phase showed a preferential accumulation of the linear
form of PFOA and PFNA over the branched chain iso-
mers. Thus, most of the branched chain PFCA isomers
were more quickly eliminated than were the linear
forms. No statistically significant differences in rate of
elimination of branched chain or linear isomers of PFOS
were found. Additional exceptions for two small ECF
PFOA isomers and 1m-PFOS exist. In general, female
rats excrete PFCs more rapidly than male rats [130].
Olsen et al. [131] studied the pharmacokinetic beha-
vior of PFBS in rats, monkeys, and humans. Rats
received an intravenous PFBS dose of 30 mg/kg BW
and monkeys, a dose of 10 mg/kg BW. Serum and urine
samples were collected from the animals following
application of the substance. Human participants in the
study were workers who were occupationally exposed to
PFBS. The elimination half-life of PFBS can be seen in
Table 19. PFBS is apparently excreted more rapidly than
PFHxS and PFOS by rats, monkeys, and humans,
whereby species specific differences were observed. This
indicates, also for humans, that the capacity for accumu-
lation of PFBS in serum is lower than for long-chain
homologues. PFBS excretion for humans was shown to
be via the urine [131].
Additional human PFC half-life values were calculated
on the basis of serum concentrations from 26 workers
in the fluorochemical industry. The mean time was 5.4
years for PFOS, 3.8 years for PFOA, and 8.5 years for
PFHxS [132].
The renal clearance values for PFOS are 0.012 mL/kg/
day for men and 0.019 mL/kg/day for women, which are
low in comparison with the values for the animals stu-
died. The values for renal clearance of PFOA are some-
what higher [126]. The corresponding data are
summarized in Table 20.
Renal clearance of PFOS and PFOA is therefore weak,
and the compounds have a markedly long half-life in
the human body when compared with those in other
species. This hinders the translation of results from ani-
mal experiments to humans. A gender-dependent excre-
tion of PFOS and PFOA via a hormone-regulated
mechanism seems unlikely in humans [126]. This
mechanism would also not be expected in mice or rab-
bits. In the animal model, excretion is mainly through
urine and, to a smaller extent, through feces [133,134].
Protein binding and the formation of transporters are
decisive factors in the distribution and excretion of
PFCs [15,115]. Table 19 presents a summary of the
elimination half-life values for various species of PFCs.
Toxicodynamics of perfluorinated compounds
Acute toxicity
In animal models, PFOS and PFOA demonstrate a mod-
erate acute toxicity. The lethal dose with 50% lethality
[LD50] for PFOS is 251 mg/kg BW for a single oral dose
in rats. LD50 values for PFOA range from 430 to 680
mg/kg BW with an average of 540 mg/kg BW per day
[15,17]. The lethal concentration with 50% lethality
[LC50] for 1 h inhalation of airborne dust contaminated
with PFOS was 5.2 mg/L for rats. Kennedy et al. [100]
determined an LC50 of 0.98 mg/L for inhalation of
PFOA. Inhalation of this concentration over one 4-hour
period resulted in enlargement of the liver and corneal
opacity in rats.
Glaza et al. [135] determined a dermal LC50 of 2, 000
mg PFOA/kg BW in rabbits [15]. Rats and rabbits were
tested in another study on the dermal toxicity of APFO
by Kennedy [99]. Dermal application of 0.5 g APFO for
24 h caused light skin irritation in rabbits.
Skin irritation was less pronounced in rats than in
rabbits. Irritation of the skin and eyes by PFOS was not
observed in albino New Zealand rabbits. ([136] cited in
Table 17 Excretion of PFOS and PFOA by young chickens
Parameter PFOS PFOA
Excretion half-life 125 days 4.6 days
Residual blood concentration at the end of the 4-week excretion phase 48% to 52% 2% to 3%
Excretion rate constant 0.023% ± 0.004% per day 0.150% ± 0.010% per day
Excretion was after a 4-week exposure and a 4-week excretion phase (from Yu et al. [171]).
Table 18 PFOA steady-state concentrations in matrices
following daily oral administration of APFO dosages on
cynomolgus monkeys
Sample matrix Dose
3 mg/kg 10 mg/kg 20 mg/kg
Serum 81 mg/L 99 mg/L 156 mg/L
Urine 53 mg/L 166 mg/L 181 mg/L
Feces 7 mg/kg 28 mg/kg 50 mg/kg
Liver 16 mg/kg 14 mg/kg 50 mg/kg
from Butenhoff et al. [283]
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EFSA [15]). PFOS was shown to be more toxic than
PFOA in studies of fresh water organisms such as water
flea, water snails, shrimp, and planaria. Ji et al. [137]
even alluded to a toxicity of PFOS 10 times higher than
PFOA in such organisms. The lowest LC50 for fish is a
96-h LC50 of 4.7 mg/L to the fathead minnow Pime-
phales promelas for the lithium salt [134]. Table 21
summarizes the various LD50 and LC50 values.
Subacute and subchronic toxicities
Studies have shown that the primary effects of subacute
and/or subchronic toxicities induced by repetitive appli-
cations of PFOS and PFOA varied according to species:
hypertrophy and vacuolization of the liver, reduction of
serum cholesterol, reduction of triglycerides in serum,
reduction in body weight gain or body weight, and
increased mortality.
The most sensitive target organs for repetitive oral
application of PFOS over a period of 4 weeks to 2 years
in rats and cynomolgus monkeys were the liver and
thyroid. The liver was also the most sensitive target
organ for repetitive applications of PFOA in mice, rats,
and primates. The effects observed include increased
weight of liver, increases in enzymatic activity of transa-
minases in serum (alanine aminotransferase [ALT],
aspartate aminotransferase [AST]), hepaticellular hyper-
trophy, vacuolization, and liver necrosis (17, [127] cited
in EFSA [15]). A 28-day study on the oral toxicity of
PFOA showed increased mortality, dose-dependent
reduction in weight gain and increase in liver weight in
rats and mice that had received 30 mg/kg in their feed
or 50 mg/L in their drinking water ([138,139]; [140]
cited in EFSA [15]).
No evidence of disease or increase in mortality rate
was observed in a 90-day study (13 weeks) on male rats.
An increase in weight loss was observed in the group
which received the highest dosage of APFO (6.5 mg/kg
Table 19 Elimination half-lives by various species according to perfluorinated compound and gender
Species PFOS PFOA PFHxS PFBA PFBS References























Chang et al. [285]; Johnson et al. [98]; Olsen et al. [131]
Mouse - 17 days 19 days - - 3 h 7 h - Chang et al. [285]; Lau et al. [161]
Rabbit - 7 h 5.5 h - - - - - Hundley et al. [133]




- - - - - Hanhijarvi et al. [286]
Monkey 150
days












Butenhoff et al. [125]; Chang et al. [285]; Buttenhoff et al. [283]; Olsen et







- - 30 days
25.8
days
Olsen et al. [85,131,132]
F, female; M, male; PFBA, perfluorobutane acid; (from Lau et al. [115] amended and expanded).
Table 20 PFOS and PFOA renal clearance and serum half-life in humans compared with monkeys and rats
Substance Species Gender Renal clearance (mL/day/kg) Serum half-life in days
PFOS Human Female (48 kg) 0.019 n.r.
Male (61 kg) 0.012 3, 165
Cynomolgus monkey Male n.r. 200
PFOA Human Female (48 kg) 0.027 n.r.
Male (61 kg) 0.033 1, 573
Japanese macaque Female 32 2.7
Male 15 5.6
Wistar rat Female 1, 054 0.08
Male 46.1 5.63
Adapted from Harada et al. [126]; n.r., not reported.
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BW/day), at a dosage of 0.64 mg/kg BW/day, and
increased levels of palmitoyl-CoA-oxidase activity, a
marker for peroxisome proliferation.
In addition, liver weight increased. Histopathological
changes included hypertrophy and necrosis of the liver
cells. Levels of estradiol, testosterone, and luteinizing
hormone [LH] remained unchanged. The PFOA concen-
trations in serum, measured after treatment with various
APFO doses, are shown in Table 22. The ‘no observed
adverse effect level’ [NOAEL] determined in this study
was 0.06 mg/kg since a dose of 0.64 mg/kg BW/day and
above resulted in reversible changes to the liver [141].
Liver toxicity was also described in rats after inhala-
tion and dermal uptake of PFCs. An increase in mortal-
ity rates was observed after inhalation exposure to
PFOA. Based on non-neoplastic effects in the liver at
the next higher dosage, the NOAEL was noted as 0.14
to 0.16 mg/kg BW/day [127].
Further studies show that the toxicity profiles of L-
PFOA, 80% linear and 20% branched chain PFOA, as
well as 100% branched chain PFOA are similar. How-
ever, the branched chain form is less effective than the
pure linear form. The ‘lowest observed adverse effect
level’ [LOAEL] in rats was higher for linear and
branched chain isomers (1 mg/kg BW/day) than the
LOAEL for the purely linear application form of PFOA
(0.3 mg/kg BW/day). The LOAEL in these studies was
based on the reduction of cholesterol and triglyceride
levels in the blood of rats. This LOAEL was equivalent
to a PFOA serum concentration of 20 to 51 mg/L in
rats ([142] cited in EFSA [15]). These observations are
in agreement with the conclusion drawn above that
branched chain isomers are generally excreted more
rapidly than the linear forms [129,130].
Seacat et al. [108] assumed a NOAEL for PFOS of
0.34 to 0.4 mg/kg BW/day when ingested by rats with
their food. This was the lowest dose for which an effect
could be observed over a time period of 14 weeks in
male rats. Nonetheless, this dose was denoted as
NOAEL, whereby the observed hepatocellular hypertro-
phy and vacuolization were marginal [108].
Curran et al. [143] undertook a detailed and extensive
study of subacute toxicity of PFOS in rats. The authors
exposed Sprague-Dawley rats to doses of 2, 20, 50, or
100 mg PFOS/kg in the feed over a period of 28 days.
At low dosages, PFOS accumulated primarily in the
liver and at lower concentrations, in other organs such
as the spleen and heart, as well as in the serum. The
PFOS concentrations in the serum and other organs
were seen to rise at higher dosages (50 and 100 mg/kg
food). The results of this study confirm that the liver is
the target organ for PFOS. Hepatomegaly, reduced tri-
glyceride and cholesterol levels in serum, increased the
expression of the gene for acyl-coenzyme A-oxidase 1
(ACOX1) and of cytochrome P450 4A22 (CYP4A22) are
all indications of exposure to a peroxisome proliferator.
Changes in fatty acid profiles in the liver encompass an
increase in the total amount of simple unsaturated fatty
acids, a loss in the total amount of polyunsaturated fatty
acids as well as an increase in linoleic acid concentra-
tion and a reduction of long-chain fatty acids. These
changes also portend to a weak peroxisome proliferator.
The authors suggest that the fatty acid dysfunctions in
the liver may possibly be the cause of changes in the
Table 21 LD50 and LC50 values for PFOS and PFOA (from [15]; BfR [17] enhanced)
Criterion PFOS PFOA Animal species Reference




0.98 mg/L, inhalation Rat Kennedy [100]
LD50 n.r. 4, 300 mg/kg APFO,
dermal
Rabbit Kennedy [99]
LD50 n.r. 7, 000 mg/kg









27 to 233 mg/L
10 to 178 mg/L
181 to 732 mg/L
337 to 672 mg/L
Four fresh water species (water flea, water snail, shrimp,
planarian)
Li [288]
LC50 18 mg/L 200 mg/L Japanese water flea Ji et al. [137]
n.r., Not reported.
Table 22 PFOA serum concentrations of male rats after a
90-day exposure to various dosages of APFO
Dosage (mg APFO/kg feed/
day)






Adapted from Perkins et al. [141].
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cell membranes in red blood cells, seen as an increase in
lysis and cell fragility. Concentrations of the thyroid hor-
mones tri-iodo thyronine [T3] and thyroxine [T4] were
lowered in PFOS-exposed rats. The kidneys and the car-
diovascular system do not seem to be influenced by
PFOS. The LOAEL in this study was 20 mg PFOS/kg
feed for male rats and 2 mg PFOS/kg feed for female
rats based on increased liver weight and reduced body
weight. At these dosages, the animals had serum con-
centrations of 13.5 or 1.5 mg PFOS/kg, respectively
[143].
In a study on the subacute toxicity of PFCs in rats,
Cui et al. [144] determined that the liver, the lungs, and
the kidneys were the main target organs for these sub-
stances. They exposed Sprague-Dawley rats to PFOS or
PFOA at concentrations of 5 and 20 mg/kg BW/day,
respectively, for 28 days. Changes were observed in the
group with the highest PFOS dose (20 mg/kg/day)
including reduced activity, lethargy, reduced food
uptake, and an apparent loss of body weight. Hypertro-
phy and cytoplasmic vacuolization of the liver and
epithelial cells induced pleural thickening. The highest
PFOA concentrations after a 28-day exposure were mea-
sured in the kidneys (228 ± 37 mg/kg at a dosage of 5
mg/kg/day). The highest PFOS concentrations were 648
± 17 mg/kg in the liver following an exposure of 20 mg/
kg/day for 28 days. The increased accumulation of
PFOS may explain the higher toxicity of this substance
[144].
In a 90-day study on the oral toxicity of PFOA in rhe-
sus monkeys, all four of the animals in the group that
received 100 mg/kg BW/day died within 5 weeks, and
three monkeys of the group that received 30 mg/kg
BW/day died in the 13th week. Loss of heart and brain
masses was detected in female animals that received 10
mg/kg BW/day. PFOA-induced organ damage could be
observed in animals that received 3 to 10 mg/kg BW/
day. The only change seen in the monkeys that received
the lowest dosage (3 mg/kg BW/day) was a slight diar-
rhea [145,15].
In a study, a six-month oral APFO exposure of cyno-
molgus monkeys indicated a dose-dependent increase in
liver weight in association with a proliferation of the
mitochondria. No histological evidence of liver damage
was observed in the low-dosage range (3 to 10 mg/kg
BW/day). In addition, no changes were observed in clin-
ical parameters of hormones, urine, or blood composi-
tion that could be attributed to treatment with APFO. It
must be noted, however, that the groups were made up
of only four to six animals, whereby one monkey from
the group receiving the lowest dosage was replaced
because of bacterial septicemia, and the highest dosage
was lowered retroactively due to weight loss and a
reduction in food uptake by the animals [146].
In a study by Seacat et al. [128], doses of 0.03, 0.15,
and 0.75 mg PFOS/kg BW/day were applied directly to
the stomach of cynomolgus monkeys for 26 weeks. His-
topathological changes were detected in the liver at the
highest dosage. At the lowest dosages, changes in serum
concentrations of thyroid hormones (thyroid stimulating
hormone [TSH], T3) were observed. High-density lipo-
protein [HDL] and cholesterol levels were also changed.
The observed effects in dependence upon dosage in
male and female monkeys are shown in Table 23. The
clinical changes and the effects on the liver had comple-
tely disappeared 211 days after treatment. This reversi-
bility of the effects was accompanied by a significant
reduction in PFOS concentration in the serum and in
the liver [128].
In both the cynomolgus monkey and in the rat stu-
dies, a steep dose-effect relationship for PFOS was con-
spicuous. The dose-effect curve for PFOA in rats was
less steep than that for PFOS ([17] cited Perkins et al.
[141]).
Subacute toxic effects of PFC exposure were also
observed in fish. Yang [147] put Japanese Girardinus
guppies in sea water containing 10, 50, or 100 mg/L
PFOA for 7 days. Neither survival rate nor relative liver
and gonad size or growth was affected by this concen-
tration. Peroxisomal acyl-CoA-oxidase activity was, how-
ever, increased at the highest dosage. This was
accompanied by a significant increase in the peroxisome
proliferator activated receptor [PPAR]a expression.
PFOA induced a significant inhibition of catalase activity
at a high dosage, without causing changes in the super-
oxide dismutase or glutathione peroxidase level in the
liver. This suggests that PFOA causes an induction of
the peroxisomal fatty acid oxidation and an increase in
oxidative stress by changing the cellular oxidative home-
ostasis in the liver. Furthermore, PFOA increases the
mRNA concentration of proinflammatory cytokines
such as IL-6, TNF-a, and IL-1b suggesting that inflam-
mation and tissue damage may be involved [45].
Table 23 Changes in male and female cynomolgus
monkeys after daily application of various dosages of
PFOS
Change PFOS dosage (mg/kg BW)
0 0.03 0.15 0.75
Increased mortality ×a
Vacuolization and hypertrophy of the liver × ○
TSH level increased × × ○
T3 level lowered ○ × × ○
HDL concentration lowered × ○ × ○
Bilirubin concentration dropping ×
Cholesterol concentration dropping × ○
Changes in male (cross) and female (empty circle) monkeys; atwo of six
animals. Adapted from Seacat et al. [128]; BfR [17].
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Fang et al. [148] found that a 14-day exposure of rare
minnows to PFOA caused a change in the expression of
apolipoproteins and upstream genes (PPARa, PPARg,
HNF4a). These changes in gene expression can influ-
ence lipid metabolism or other physiological functions
in fish. Results from studies on subacute and subchronic
toxicities of PFCs are summarized in Table 24.
Chronic toxicity and carcinogenicity
In a study on chronic toxicity and carcinogenicity of
PFOS, groups of 40 to 70 male and female rats were fed
with the potassium salt of PFOS in doses of 0.5, 2, 5,
and 20 mg/kg mixed with their feed for 104 weeks. An
additional comparison group received the maximum
PFOS dose for 52 weeks, followed by 52 weeks of con-
trol diet without PFOS exposure. Hepatotoxic and carci-
nogenic effects were observed in the rats after PFOS
exposure. Based on the hepatotoxic effects, a NOAEL of
2 mg/kg feed or 0.14 mg/kg BW/day was calculated for
male and female rats ([17,149] cited in EFSA [15]). The
observed effects in rats according to dose and frequency
are shown in detail in Table 25.
A study by Sibinski [150] on chronic exposure to
PFOA showed an increased incidence of Leydig cell ade-
nomas. The incidence of breast fibroadenomas was not
significantly or dose-dependently increased over the
control values. The 50 male and 50 female ratse were
fed 30 or 300 mg/kg APFO with their feed for a period
of 2 years. A dose-dependent decrease in weight gain
was observed in male rats and, to a lesser extent, in
female rats. The decrease was statistically significant for
both male and female animals that received the maxi-
mum dosage. Comparison of survival rates, urinalyses,
and opthalmological examinations did not show any sig-
nificant differences from the control animals. Additional
effects observed after exposure to APFO are presented
in Table 26. The biological significance of ovarian
damage was questioned by the authors due to the lack
of evidence of tumorigenesis. According to an evaluation
by Mann and Frame [151], the effects on the ovaries
were in the form of gonadal hyperplasias and/or adeno-
mas. The NOAEL for male rats, based on increased liver
weight and liver anomalies, was 1.3 mg PFOA/kg BW.
For females, the NOAEL was listed as 1.6 mg PFOA/kg
BW/day since higher dosages led to reduced body
weight and changes in blood values [15].
A pathology work group evaluated the appearance of
proliferative injury to mammary glands in female rats
that had been fed APFO for 2 years. Using documents
Table 24 Data from studies on subacute and subchronic toxicities of PFOS and PFOA
Substance Exposure
period
Species Target organ/Effect Effective
dosagea
NOAELa Reference
PFOS 28 days Rats Body weight ↓, liver mass ↑, and altered gene expression and fatty










Centrilobular vacuolization, hypertrophy of the liver, T3 ↓, TSH ↑, HDL
↓, and bilirubin, cholesterol concentrations ↓







Deterioration of behavioral and activity parameters (larvae were less






PFOA 7 days Japanese guppies Activity of peroxisomal acyl-CoA-oxidase ↑ and significant inhibition
of catalase activity, mRNA concentration proinflammatory cytokines




14 days Minnows Changes in the expression of apolipoproteins and upstream genes
(PPARa, PPARg, HNF4a)
n.r. n.r. Fang et al.
[148]
90 days Rats (male) Liver mass ↑ and hepatocellular necrosis 1.7 0.6 Goldenthal
[290]






90 days Rats (male) Absolute and relative liver mass ↑, hepatocellular hypertrophy, and
effects were reversible
0.64 0.06 Perkins et
al. [141]









3 weeks Chicks (male) No significant effects n.r. > 1 Yeung et
al. [284]
aEffective dosage and NOAEL without further specifications are presented in milligrams per kilogram per body weight per day. Upward arrow, increased;
downward arrow, decreased; n.r., not reported; T3: tri-iodo thyronine; T4, thyroxin.
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from the study of Sibinski [150], they came to the con-
clusion that the incidence of mammary gland tumors
was not changed by chronic exposure to APFO. Feeding
female rats (see Table 26) as much as 300 mg/kg APFO
did not result in an increase in proliferative damage to
breast tissue [152].
In an additional study on the carcinogenicity of APFO,
rats were fed 300 mg APFO/kg of food, equivalent to ca.
14 mg/kg BW/day for 2 years. The study encompassed
153 rats, and an additional 80 animals formed the con-
trol group. Hormone status, cell proliferation, and per-
oxisome proliferation were measured. Increases in liver
weight and b-oxidation activity of the liver were statisti-
cally significant throughout the whole test period,
whereas increases in weight of the testicles only
occurred at 24 months. No differences were detected
between the exposed rats and the control animals in
regard to serum concentrations of testosterone, follicle-
stimulating hormone [FSH], LH, or prolactin. An
increased incidence of Leydig cell adenomas was seen in
the exposed group (8/76) when compared with the con-
trol group (0/80) as well as liver adenomas (10/76 vs. 2/
80) and pancreas cell tumors (7/77 vs. 0/80). The num-
bers in brackets show the observed cases and total num-
ber of animals in the groups of exposed and control
animals [153]. Further studies showed that an APFO
dosage of 14.2 mg/kg BW/day increases the incidence of
damage to proliferating pancreas cells; however, it does
not increase the incidence of adenomas or carcinomas
([17,154] cited in EFSA [15]).
Sibinski [150] and Biegel et al. [153] both showed that
PFOA or PFOS induces liver-cell adenomas, Leydig cell
adenomas, and hyperplasia of acinar pancreas cells.
Furthermore, it could be shown that PFOA functions as
promoter in liver carcinogenesis of male Wistar rats.
The rats were treated with 0.02% APFO in their feed,
and 200 mg/kg BW/day of diethylnitrosamine served as
initiator ([155,156] cited in EFSA [15]).
Genotoxicity and epigenetic effects
In various in vitro and in vivo test systems, PFOS and
PFOA did not appear to be genotoxic. Therefore, it can
be assumed that the carcinogenic effects are the result
of an epigenetic mechanism and that the trigger is a
threshold concentration, i.e., apparently a dosage exists
beneath which a carcinogenic effect would not be
expected [17].
Based on a number of in vitro and in vivo tests con-
cerning gene and/or chromosome mutagenicity or the
induction of unscheduled gene repair, the EFSA also
assumes that PFOS is not genotoxic. PFOS does not
Table 25 Observed effects in a study of chronic exposure of rats to PFOS
Category Effects Occurrence, dosage, and frequency (Cases/Total number)
Hepatotoxicity Increase in centrolobular hypertrophy, eosinophilic granuloma,
and vacuolization of liver cells
(a) Male rats, 2 mg/kg of feed




Mild to moderate hyperplasia of the smooth endoplasmic
reticulum, minimal to mild hypertrophy of liver cells, and no
peroxisome proliferation
In a proportion of the animals that received 20 mg/kg of feed
Neoplastic
effects
Significant increase in the incidence of (a) adenomas of the liver,
(b) follicular adenomas of the thyroid, (c) hepatocellular
adenomas, carcinomas, (d) follicular adenomas and carcinomas of
the thyroid, (e) fibrocystic breast adenomas/adenomas, and (f)
fibrocystic breast adenomas/adenomas/carcinomas
(a) Male rats, 20 mg/kg of feed (7/60), control (0/60)
(b) Comparison group (9/39), control (3/60), group with highest
dosage (4/59)
(c) Female rats, 20 mg/kg of feed
(d) Female rats, 5 mg/kg of feed (3/50), control (0/60)
(e) Female rats with the exception of the group with the highest
dosage
(f) Female rats, 0.5 mg/kg of feed (36/50), 2 mg/kg (31/48), but
not for the group with 5 and 20 mg/kg of feed (29/50 and 24/
60), control (29/60)
Adapted from Thomford [149] cited in EFSA [15].
Table 26 Effects on rats after a 104-week application of APFO (from Sibinski [150]; EFSA [15])




(a) Slight reduction in number of erythrocytes and packed cell volume, liver mass, liver
nodules, Leydig cell mass ↑; (b) number of white blood cells ↑ and AST, ALT, alkaline
phosphatase, and creatine phosphokinase ↑; (c) breast tissue mass ↑ and tubular
hyperplasia of the ovarian stroma; (d) kidney mass ↑ and changes in the liver
(hepatomegalocytosis, necrosis, mononuclear cell infiltration, cystoid degeneration)
(a) Male rats, 300 mg/kg
(b) Male rats, 30 mg/kg
(c) Female rats, 30 mg/kg
(d) Female rats, 300 mg/kg
Carcinogenicity (a) Incidences of testicular Leydig cell adenomas ↑ and (b) fibrocystic breast adenomas
↑
(a) Male rats, 0 mg/kg (0/50), 30 mg/kg
(2/50), 300 mg/kg (7/50)
(b) Female rats, 0 mg/kg (10/46), 30 mg/
kg (19/45), 300 mg/kg (21/44)
Upward arrow, increased.
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induce gene mutation with or without metabolic activa-
tion in a bacterial test system, does not cause chromo-
some aberrations in human lymphocytes, and does not
induce unscheduled DNA synthesis in rat hepatocytes.
PFOS does not cause formation of micronuclei in a
mouse’s bone marrow cells in vivo. Various in vitro and
in vivo genotoxicity tests for precursors of PFOS and N-
ethylperfluorooctyl sulfonamide ethanol [N-EtFOSE], N-
EtFOSA, N-methylperfluorooctyl sulfonamide ethanol
were also negative. APFO also failed to induce back
mutations in tests with Salmonella typhimurium or
Escherichia coli, both with or without metabolic activa-
tion. APFO did not cause chromosome aberrations in
human lymphocytes or in ovary cells of Chinese ham-
sters, with or without metabolic activation, nor did it
lead to cell transformation in mouse embryo fibroblasts.
An in vivo micronuclear test on mice treated with
PFOA was also negative [15].
Murli et al. [157] twice tested the potential of APFO
to cause chromosome aberrations in cells of the Chinese
hamster. In the first test, the results were positive, both
with and without metabolic activations, i.e., chromo-
some damage was observed. In the second test, APFO
induced chromosome aberrations and polyploidy only
without activation. However, these effects were only
observed at cytotoxic concentrations of APFO [15].
In the study by Yao and Zhong [158], PFOA was seen
to induce not only DNA strand breaks, but also
increased concentrations of reactive oxygen species and
8-hdroxydesoyguanosine [8-dG]. This result suggests
that the observed genotoxic effects are induced by an
oxidative damage to the DNA or by intracellular ROS.
Takagi et al [159] also detected significantly increased 8-
dG concentrations.
Reproductive and developmental toxicity
PFOS and PFOA neither interfered with reproduction
nor did they lead to any appreciable teratogenic effects.
Both substances did, however, show developmental toxi-
city when the mother animal was exposed during preg-
nancy, i.e., they led to a reduced increase in body weight
after birth and reduced the number of live births and
the viability of the progeny in the first five days after
birth [15,17,115,134,160,161].
For example, in a study by Lau et al. [162], all live-
born young rats, born to a mother that was exposed to
10 mg PFOS/kg BW/day during gestation, were pallid,
inactive, became moribund within 30 to 60 min, and
died shortly thereafter. The offspring of mother animals
that received 5 mg PFOS/kg BW/day, survived for 8 to
12 h. This could also be observed in progeny of mother
animals that received 20 or 15 mg/kg BW/day. However,
95% of these progeny died within the first 24 h after
birth. Approximately 50% of the progeny died when the
mother animal received 3 mg PFOS/kg BW/day (rat) or
10 mg/kg BW/day (mouse). Wet nursing the progeny by
a non-exposed control animal did not improve their via-
bility. Prenatally exposed rats and mice that did survive
showed delays in growth and opening of the eyes.
Exposed young mice had significantly higher liver weight
and lower T4 concentrations in serum but unchanged
T3 and TSH concentrations when compared with non-
PFOS-exposed animals [162].
In a two-generation study on rats, Lübker et al. [163]
found fertility parameters unchanged after oral applica-
tion of the maximal PFOS concentration was tested (3.2
mg/kg BW/day).
In another two-generation study on rats, the progeny
of PFOS-exposed mother animals (LOAEL = 0.4 mg/kg
BW/day) were found to gain body weight more slowly
in the F1 generation and to have reduced birth weight
in the F2 generation. The serum concentrations of the
animals (F0) on the 21st day of gestation were 26.2 mg/
kg and of the fetuses, 34.4 mg/kg (liver- and serum-
pooled). The NOAEL was calculated to be 0.1 mg/kg
BW/day ([164] cited in EFSA [15]).
Unaltered fertility parameters were found in yet
another two-generation study of PFOA-exposed rats by
Buttenhoff [165]. The highest dosage in this study was
30 mg/kg BW/day. No signs of maternal toxicity were
observed in the animals at exposures up to this dosage.
However, compared with those in control animals, the
adult body weight of the progeny was lower and liver
and kidney weights were higher even at the lowest
dosage tested, 1 mg/kg BW/day. The mortality rate of
the progeny was increased at 30 mg/kg BW/day, which
is the highest dosage tested [17].
Because of allusions to a correlation between PFOA
serum concentrations with a reduced sperm count in
young Danish adults and/or a longer period before preg-
nancy occurred, York et al. [166] reevaluated these two-
generation studies. Testicular and sperm structures and
functions, however, were unchanged in APFO-treated
rats with an average PFOA serum concentration as high
as 50, 000 μg/L. Since the PFOA concentration in the
Danish cohort was 5 μg/L, the authors assume that
there is no causal relationship between PFOA concen-
trations in serum and a reduction in sperm count in
these men [166].
Lau et al. [161] carried out studies on the develop-
mental toxicology of PFOA using mice since the excre-
tion of PFOA in female rats is so rapid that these
animals were not considered appropriate experimental
subjects for these tests. Effects (increased liver weight)
were observed in the mother animals exposed to a
dosage of 1 mg/kg BW/day or higher. Increased resorp-
tion of fetuses and reduction of survival rate and body
weight gain of the live-born progeny were observed
when mother animals received dosages of 3 mg/kg BW/
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day. These effects exhibited a steep dose-response curve.
The resorption of all of the fetuses in a litter during
gestation (full-litter resorption) which resulted from a
dosage of 5 mg PFOA/kg BW/day or higher was parti-
cularly striking [17,161].
Grasty et al. [167] set out to determine a critical time
period of gestation for effects of prenatal exposure using
Sprague-Dawley rats. The authors administered 25 mg/
kg BW of the potassium salt of PFOS on GD 2 to 5, 6
to 9, 10 to 13, 14 to 17, and 17 to 20 or 25 or 50 mg/kg
BW on day19 to 20. Neonatal mortality was observed
for all of the time periods; however, the incidence of
stillbirths increased with the PFOS exposure at later
periods of gestation, reaching 100% for prenatal expo-
sure on GD 17 to 20. Exposure to PFOS in the late
phases of gestation is apparently adequate to induce
effects that are toxic to reproduction. This result sug-
gests that PFOS damages the organs that develop in the
last phases of gestation. Grasty et al. [168] therefore
examined the lungs of newborn rats and discovered
thickening of the alveolar walls of prenatal PFOS-
exposed young animals. However, as a result of the nor-
mal phospholipid profile of the lungs and the fact that
treatment with dexamethasone or retinylpalmitate did
not ameliorate the situation, it must be concluded that
the neonatal mortality is not due to the immaturity of
the lungs [15]. Lau et al. [115] mentioned studies that
suggest an effect of PFCs on the pulmonary surfactants,
e.g., dipalmitoylphosphatidylcholine. In a study in which
PFOA was exclusively applied in the late phase of gesta-
tion, it was also shown that this treatment was adequate
to trigger developmental toxic effects in mice ([169]
cited in BfR [17]).
In a cross-fostering study, Lübker et al. [170] observed
that neonatal mortality was also high in progeny that
had been exposed to PFOS in utero but which had not
been exposed to any further PFOS in milk. Compared
with control animals, a diminished gain in body weight
was also noted in animals that were only exposed to
PFOS via the milk they drank, but were not the progeny
of PFOS-treated mother animals [17,115].
Yu et al. [171], in another cross-fostering study,
observed that both pre- and postnatal PFOS exposures
(3.2 mg/kg feed) lower the T4 concentration in the pre-
natally exposed progeny. On days 21 and 35 after birth,
the T4 concentrations were reduced by 20.3% or 19.4%,
and in postnatally exposed rats, by 28.6% or 35.9% com-
pared with control animals.
Liu et al. [113] injected young mice with 50 mg/kg
BW PFOS on different days after birth. They then mea-
sured, among other things, the concentration of maleic
acid dialdehyde, superoxide dismutase [SOD] activity,
and the total antioxidative capacity [T-AOC] as para-
meters of oxidative damage that might be occurring.
PFOS induced a loss of body weight in mice and an
increase in the relative weight of the liver. It also sup-
pressed SOD activity and diminished the T-AOC in the
brain and liver. Younger mice were more sensitive to
the effects of PFOS than older animals [113].
Abbott et al. [172] studied the influence of PPARa on
the PFOA-induced developmental toxicity using wild-
type and PPARa knockout mice. The authors adminis-
tered oral dosages of 0.1, 0.3, 0.6, 1, 3, 5, 10, and 20
mg/kg BW on the 1st to the 17th GD. (The effects are
described in Table 17). Resorption of all fetuses of a
mother animal through the administration of 5 mg
PFOA/kg BW/day occurred as frequently in the PPARa-
deficient mice as in the wild-type animals. The effects of
PFOA cannot therefore be attributed fully to the activa-
tion of PPARa. PPARa does, however, seem to play a
role in the delayed opening of eyes and the postnatal
reduction in weight gain [15,17,172]. Abbott et al. [173]
came to the conclusion that the developmental toxicity
effects are not dependent upon the activation of PPARa
by PFOS. The wild-type mice were just as sensitive to
the effects of neonatal lethality as were the PPARa-
knockout mice. Furthermore, it can be seen from this
publication that PPARa, b, and g are expressed in early
developmental phases in embryos of rodents and
humans. The expression patterns depend upon the
developmental stage and the type of tissue, leading to
the assumption that PPARa, b, and g play important
functions in many cell types and organs during develop-
ment [173].
The influences on reproduction by PFOS and PFOA
are not limited to mammals but have, for example, also
shown to affect chickens [174-176], quail, mallard duck
[177], frogs, and fish ([178,179] cited in Lau et al. [115]).
The following observations stem from studies on the
developmental and reproductive toxicity of other PFCs:
The toxic effects of N-Et-FOSE are similar to those of
PFOS. This may be explained by the transformation of
N-Et-FOSE into PFOS; however, N-Et-FOSE was also
seen to increase the number of stillbirths and mortality
of the newborn in the F2 generation of rats ([163,164]
cited in Lau et al. [115]). The effects of 8:2 FTOH on
rats were slightly similar to those of PFOA into which
FTOH can be transformed. The NOAEL for 8:2 FTOH
was determined to be 200 mg/kg BW/day ([58] cited in
Lau et al. [115]). PFBS did not elicit a verifiable develop-
mental effect in rats [115]. In contrast to observations
on PFOS and PFOA, exposure of pregnant mice to
PFBA was not found to have adverse effects on survival
of newborn or their postnatal growth [180]. Although
PFHxS, compared with PFBS, PFOS and PFOA, has the
longest half-life in humans, no effects on reproduction
or survival and growth of the progeny was observed in
rats. The NOAEL for developmental toxicity of PFHxS
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was determined to be 10 mg/kg BW/day ([181] cited in
Lau et al. [115]). Perfluorodecanoic acid, like other
PFCs, did not induce deformations and also did not eli-
cit any other developmental toxic effects [182].
PFNA led to cell apoptosis in testicles of male rats.
The animals received oral doses of 1, 3, and 5 mg/kg/
day for 14 days. The results imply that the ‘death recep-
tor pathway’ is the chief mediator for apoptosis in the
kidneys which is a result of PFNA exposure. It is not yet
known whether PFNA induces the changes in Fas and
FasL expressions directly or whether the imbalance
between testosterone and estradiol, which causes germ
cell apoptosis, is involved in the Fas/FasL pathway [183].
Table 27 presents a survey of the studies on reproduc-
tion and developmental toxicity of PFOS, PFOA, and
other PFCs.
Neurotoxicity
A study by Austin et al [107] showed that PFOS can
have an influence on the neuroendocrine system in rats.
The authors discovered reduced food intake and body
weight, influence on the ovarian cycle, increased corti-
costerone concentration, and decreasing leptin concen-
tration in serum as effects of PFOS exposure. In
addition, noradrenaline concentrations in the paraventri-
cular nucleus of the hypothalamus were elevated.
In an in vitro study, Harada et al. [184] observed that
PFOS increases the negative charge density in the cell
membrane of Purkinje cells, e.g., nerve cells in the cere-
bellum, of rats. It also reduced the membrane potential,
leading to hyperpolarization and thus influencing activa-
tion and inactivation of the ion channels. This appears
to indicate that PFOS has an effect on the action poten-
tial in nerve cells [185].
Slotkin et al. [186] tested the neurotoxicity of PFOS,
PFOA, FOSA, and PFBS in an in vitro experiment on
undifferentiated and differentiated PC12 cells. After
addition of the substances, the authors examined the
cells for inhibition of DNA production, deficits in cell
numbers and growth, oxidative stress, reduced viability,
as well as changes in the production of the neurotrans-
mitters, dopamine and acetylcholine. They came to the
conclusion that the different PFCs do not exhibit the
same influence on neurons and that it is unlikely that a
simple, mutual mechanism is behind all of the neuro-
toxic effects. FOSA exhibited the strongest effects on
the cells, followed by PFOS and PFBS, and finally,
PFOA. FOSA depressed DNA production, caused oxida-
tive stress, and reduced the viability of the cells. An
explanation for the stronger toxic potential of FOSA is
most likely the increased hydrophobicity of this com-
pound and the inherently enhanced access to the cell
membrane [186].
In their study, Liao et al. [187] also came to the con-
clusion that the effects of PFCs on the neurons of the
hippocampus of rats are dependent upon the length of
the carbon chains and on the functional groups on the
alkyl chains. The influence of PFCs on synaptic trans-
mission, calcium current, and neurite growth were
examined. Longer chain compounds or such that have a
sulfonate group appeared to have stronger effects than
short-chain PFCs with a carboxylate group. For example,
the experiments with PFOS and PFTDA displayed the
highest frequency and strongest amplitude of sponta-
neous miniature postsynaptic currents [187].
Ten-day old mice received a single dose of 0.75 or
11.3 mg PFOS/kg BW, 0.58 or 8.7 mg PFOA/kg BW, or
0.72 or 10.8 mg PFDA/kg BW in their stomachs. Their
spontaneous behavior, defined as movement, breeding
behavior, and total activity, as well as their habits were
then observed at 2 and 4 months. Behavioral abnormal-
ities were observed in the mice that were exposed to
PFOS and PFOA. These appeared as a reduced or defi-
cient adaptability and hyperactivity of the adult mice.
These effects became stronger with age. An effect on
the cholinergic system was examined using the nicotine-
induced spontaneous behavior test on 4-month old ani-
mals. The response to nicotine was hypoactivity in
exposed animals in contrast with a hyperactive response
to nicotine in control animals. Based on the response to
nicotine, the effects appear to be mediated by the choli-
nergic system. These neurotoxic changes are similar to
those induced by other POPs such as PCB [15,188]. In a
subsequent study on mice, Johansson et al. [189] also
showed that PFOS and PFOA increased the concentra-
tions of proteins that are necessary for normal brain
development, the tau protein and synaptophysin. Tau
proteins play a role in the pathogenesis of Alzheimer’s
disease, and synaptophysin is a membrane protein of
synaptic vesicles [190]. Altered concentrations of these
proteins could possibly explain the behavioral changes
described above [189].
According to the results of Sato et al. [191], a single
dose of PFOS (≥250 mg/kg in rats, ≥125 mg/kg in mice)
caused tonic spasms; however, ultrasound stimulus was
required as trigger. Even with ultrasound stimulus,
PFOA was not found to cause spasms. Changes in neu-
rotransmitter concentrations in the brain or damage to
nerve cells did not occur. Therefore, it was not possible
to finally elucidate the mechanism responsible for the
spasms. PFOS concentrations in the brain (20 to 25 mg/
kg) were always lower than those in the liver, kidneys,
or serum and increased with passing time after applica-
tion [191].
The developmental neurotoxic effects were studied in
a further in vivo study. Rats were fed 7.2 or 14.4 mg
PFOS/kg of feed from the beginning of gestation until
30 days after birth. The cross-fostering method was
used to differentiate between pre- and postnatal
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Table 27 Studies on the reproduction and developmental toxicity of PFCs (from EFSA [15] and enhanced)
Substance Experimental
animal
Tested dosage and time point Effects NOAEL
LOAELa
Reference
PFOS Rats 1, 5, and 10 mg/kg BW/day; GD 6 to
15






Rats 5 and 10 mg/kg BW/day; GD 6 to 15 Weight loss of the maternal animal and
developmental toxic effects: birth weight ↓,
inner organ abnormalities, delayed




Rats 1, 2, 3, 5, and 10 mg/kg BW/day; GD
2 to 21
Weight gain of the maternal animal ↓; serum
T4 and T3 of the maternal animal ↓; at the
highest dosage: body weight of the fetus ↓,
cleft palate, anasarca, death rate 4 to 6 h after
birth ↑; and from 2 mg/kg BW/day: postnatal
growth rate, delayed opening of eyes, T4 ↓
n.r. Lau et al. [162];
Thiobodeaux et al.
[114]
Mice 1, 5, 10, 15, and 20 mg/kg BW/day;
GD 1 to 18
Delayed opening of eyes and from 5 mg/kg
BW/day: liver mass ↑
n.r. Lau et al. [162];
Thiobodeaux et al.
[114]
Rats 0.4, 0.8, 1, 1.2, 1.6, and 2 mg/kg BW/
day; 6 weeks before mating, during
gestation, and up to the fourth day
of nursing
From 0.8 mg/kg BW/day: gestation time and
viability of the young animals ↓
n.r. Lübker et al.
[163,170]
Rats 0.1, 0.4, 1.6, and 3.2 mg/kg BW/day;
42 days before mating, during
gestation, and nursing
At highest dosage: gestation time, number of
implantation points, and litter size ↓; and at
the second-highest dosage (F1): reduced
viability, body weight of the newborn,
delayed reflexes and physical development,






Rabbits 0.1, 1, 2.5, and 3.75 mg/kg BW/day;
GD 6 to 20
Weight gain of the maternal animal ↓;and at






Case et al. [293]
Mice 1, 10, and 20 mg/kg BW/day; GD 0
to the end of the study
At the highest dosage (maternal animal):
weight gain, feed ↓, water uptake ↑, liver
mass ↑; body weight of the fetus ↓,
enlargement of the neck, skeletal deformity;
and newborn weak and inactive, lung
atelectasis, aneurism of intracranial arteries,
respiratory dysfunction to death
n.r. Yahia et al. [294]
Leghorn
chickens
1, 2.5, and 5 mg/kg egg; before
incubation
No effect on hatching rate, spleen mass ↑,
right wings shorter, frequent occurrence of
brain asymmetry, immunoglobulin (IgM, IgY)
↓, plasma lysozyme activity ↑; at the highest
dosage: liver mass ↑; and at the highest









10, 50, and 150 mg/kg of feed Viability of the 14-day-old progeny↓; at the
lowest dosage: slight increase in incidences of
small testes (length); however,







PFOA Rats 1, 3, 10, and 30 mg/kg BW/day Body weight ↓, liver and kidney mass ↑; and
at the highest dosage: birth weight ↓,
mortality after weaning ↑, delayed puberty
n.r. Butenhoff et al.
[125,165]
Mice 1, 3, 5, 10, 20, and 40 mg/kg BW/
day; during gestation
Liver enlargement; full-term gestation, viable
fetuses, fetus weight, postnatal viability ↓; and
growth deficit, delayed opening of eyes,
accelerated sexual maturity of male progeny
n.r. Lau et al. [161]
Mice 3 to 20 mg/kg BW/day Liver mass of the maternal animal ↑; body
weight gain ↓; and application during GD 7
to 17 and 10 to 17: delayed opening of eyes
and growth of coat
n.r. Wolf et al. [169]
Mice 5 mg/kg BW/day; GD 1 to 17, 8 to
17, and 12 to 17
Body weight of young animals ↓ and
abnormal development of the nursing
process to retarded growth of progeny
n.r. White et al. [295]
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exposures. The progeny were placed in a water labyr-
inth, and immunohistochemical analysis was underta-
ken. The authors came to the conclusion that pre- and
postnatal exposures to PFOS impair spatial cognition
and memory. The mechanism could be related to a
reduction in N-methyl-D-aspartate receptor 2B [NR2B]
concentration in the cortex and hippocampal region of
the brain [192].
In a subsequent study, the authors investigated the
effects of PFOS exposure on gene expression of cal-
cium-dependent signal molecules in the hippocampus
during gestation and in the lactation period on Wistar
rats. By use of the cross-foster method, rats were pre-
and postnatally exposed to 3.2 mg PFOS/kg of feed. The
expression of NR2B, calmodulin, Ca2+/calmodulin-
dependent kinase II a, and cAMP-response element
binding protein were examined by real-time reverse-
transcriptase polymerase chain reaction. Changes in
gene expression of these molecules were detected at var-
ious time points during exposure to PFOS. It is there-
fore possible that perinatal PFOS exposure during a
critical phase of brain development exerts a neurotoxic
effect on the central nervous system via the molecules
of the calcium signal pathway [193].
Pinkas et al. [194] also confirmed the existence of
neurotoxic properties of PFOS and PFOA in developing
chickens. The authors observed the impairment of cog-
nitive performance in hatched chicks that had been
exposed to PFOS or PFOA (5 or 10 mg/kg) in ovo.
Imprinting behavior was tested on the day of hatching,
and impairment was observed after treatment with both
of the substances. In order to learn more about the
mechanism behind these effects, experiments were
undertaken on protein kinase C [PKC] isoforms (a, b, g)
in the intermedial part of the hyperstriatum ventrale,
the region most closely associated with imprinting.
Exposure to PFOA resulted in significant increases in
the cytosolic PKC concentration of all three isoforms. In
spite of the general increase in PKC expression, the
membrane-associated PKC remained unaffected, sug-
gesting a defect in PKC translocation. In contrast, PFOS
exposure resulted in reduction of cytosolic PKC, parti-
cularly in the b- and g-isoforms, but again without any
changes in the membrane-associated enzyme. Based on
these results, PFCs do appear to be developmentally
toxic. They lowered the cognitive performance after
hatching. The synaptic mechanisms behind these effects
seem to be different for PFOS and PFOA [194].
Effects on the endocrine system
The first reports of the effect of PFCs on thyroid hor-
mones were from Langley and Pilcher [195] and Gut-
shall et al. [196].
Table 27 Studies on the reproduction and developmental toxicity of PFCs (from EFSA [15] and enhanced) (Continued)
Chickens 5, 20, 40 mg/kg egg; before
incubation
Impaired hatching rate, high prevalence of
splayed legs, and chicks with partial or
complete loss of yellow pigment in the down
n.r. Yanai et al. [174]
PFBS Rats 30 to 1, 000 mg/kg No impairment of fertility or reproduction, no
developmental toxic effects aside from a
slight delay in onset of puberty, and weight
gain in male F1 rats of the group with the
highest dosage
n.r. Lau et al. [115]
PFHxS Rats n.r. No effect on fertility, reproduction, or viability
and growth of the progeny
10 York [181] cited in
Lau et al. [115]
N-Et-FOSE Rats n.r. Toxic effects similar to those of PFOS, still
birth, and mortality in the first three days ↑; in
addition, increase in the number of stillbirths
and mortality in the F2 generation
n.r. Christian et al.
[164]; Lübker et al.
[163] cited in Lau
et al. [115]
PFBA Mice 35, 175, and 350 mg/kg BW/day; GD
1 to 17
No adverse effects in regard to survival rate
of the progeny or their postnatal growth,
delayed opening of eyes, at the two highest
dosages: delayed onset of puberty, and at the
highest dosage: loss of complete litter
n.r. Das et al. [180]
PFNA Rats 1, 3, and 5 mg/kg/day; for 14 days Cell apoptosis in the testes and imbalance
between testosterone and estradiol
n.r. Feng et al. [183]
PFDA Mice 0.25, 0.5, 1, 2, 4, 8, and 16, 32 mg/kg
BW/day; GD 10 to 13 and 0.03, 0.3,
1, 3, 6.4, and 12.8 mg/kg BW/day;
GD 6 to 15
No deformities or other developmental toxic
effects; the applied dosages also did not
show toxic effects in the maternal animal
n.r. Harris and
Birnbaum [182]
8:2 FTOH Rats n.r. Only mild effects similar to those caused by
PFOA
200 Mylchreest et al.
[58] cited in Lau et
al. [115]
GD, gestation day; n.r., not reported; upward arrow, increased; downward arrow, decreased. aNOAEL/LOAEL, not reported in milligrams per kilogram body weight
per day.
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Rats that had received a dose of PFDA were found to
have significantly reduced T4 and T5 concentrations,
lower body temperature, and a slower heartbeat than
control animals. Treatment with T4 was not able to
reverse the hypothermia. Other studies on rats also
showed that PFOS exposure resulted in a reduction of
T4 and T3 in serum. There is, however, no increase in
TSH, a hormone that enhances formation of T4 and T3.
There is evidence that PFOS, similarly to PFDA, dis-
places the thyroid hormone from its binding protein as
it circulates in the blood [115].
Weiss et al. [197] examined this subject and discov-
ered that PFCs compete with T4 in binding to the thyr-
oid hormone transport protein transthyretin. This may
explain the decline in thyroid hormone levels after treat-
ment with PFCs. The binding potential of PFCs to
transthyretin decreases in the order of PFHxS > PFOS/
PFOA > perfluoroheptanoic acid > perfluor-1-octanoic
sulfinate > perfluorononanoic acid and was approxi-
mately 12.5 to 50 times lower than that of the natural
ligand of T4.
When looking at the expression of the thyroid hor-
mone-related mRNA, Yu et al. [171] only observed
changes in the expression of mRNA for transthyretin.
The transcription level for transthyretin was 150%
higher in PFOS-exposed rats than in control animals.
Chang et al. [198] discovered that the oral application
of PFOS in rats results in increased tissue availability of
thyroid hormone and an increased turnover of T4 in
connection with a reduction in the total amount of T4
in the serum. Under these conditions, PFOS neither
induced hypothyreosis nor did it alter the activity of the
hypothalamus-pituitary-thyroid axis.
Moreover, there is evidence that PFCs alter the bio-
synthesis of gender-specific steroid hormones. For
example, application of PFOA to male rats for 14 days
led to a reduction in serum and testicular testosterone
and an increase in estradiol concentration in serum.
Consequently, an increase took place in hormone synth-
esis in the liver via induction of aromatase. These hor-
monal changes most likely are connected to the
occurrence of Leydig cell adenomas observed in chronic
exposure to PFOA [115,185].
Benninghoff et al. [199] described an estrogenic
mechanism for PFOA that could promote carcinomas in
the liver of rainbow trout. In addition, PFNA, PFDA,
and PFUnA behaved like estrogens in the in vivo vitello-
genin-induction-bioassay. In the meantime, there is evi-
dence that PFCs may act as weak xenoestrogens in the
environment [115].
Wei et al. [200] described effects of PFOA on estrogen
responsive genes in the liver of minnows. The fish were
exposed to 3, 10, or 30 mg/L PFOA for 28 days. PFOA
interfered with the function of estrogen in the male fish
by inducing vitellogenin and the estrogen receptor b in
the liver. It also caused a degeneration of the ovaries in
female animals. Zhao et al. [201] showed that PFOA
inhibits 3b-hydroxysteroid-dehydrogenase and 17b-
hydroxysteroid-dehydrogenase in rat Leydig cells.
Furthermore, PFOA appears to stimulate the develop-
ment of mammary glands in C57B1/6 mice by promot-
ing steroid hormone production in the ovaries and by
increasing the concentration of a number of growth fac-
tors in the mammary glands. The results of this study
suggest an indirect estrogen effect of PFOA, the possible
utility of progesterone biomarker for PFOA exposure of
girls and women, and an independence of the PPARa
expression, for example, during tumorigenesis of the
liver [202]. Maras et al. [203] established an estrogenic
effect of 6:2 and 8:2 FTOH in vitro; however, it must be
assumed that a different mechanism is responsible for
this potential xenoestrogen than for the reference sub-
stance 17b-estradiol.
In a study of zebrafish (Danio rerio), Liu et al. [86]
determined that 8:2 FTOH exposure interferes with sex
hormone synthesis and impairs reproduction resulting
in diminished hatching rates. Four-month-old zebrafish
were subjected to 8:2 FTOH concentrations of 10, 30,
90, or 270 μg/L for 4 weeks. Testosterone [T] and estra-
diol [E2] concentrations in the plasma of the female fish
increased significantly, whereas T and E2 concentrations
in males decreased or increased. Furthermore, egg num-
bers and sperm production were reduced; the eggshells
were thinner; and the protein content and egg diameter
were lower. Histological examination showed the pro-
motion of egg-cell maturation and delayed spermiation.
Gene transcription of FSH b and LH b in the pituitary
gland was upregulated in female and downregulated in
male fish. Increased gene transcription for vitellogenin
and zona pellucida protein 2 in males is evidence of
estrogen activity. In females, the gene transcription for
these markers was reduced and was associated with
reduced fertility [86].
It was shown in a study by Shi et al. [204] that PFDoA
interferes with the reproductive function, testicular
structure, and the genes for steroidgenesis in male rats.
The rats were treated orally with 1, 5, or 10 mg PFDoA/
kg BW/day.
Subsequent testing for chronic, oral exposure to
PFDoA (over a period of 110 days) also showed inhibi-
tion of steroidgenesis in the testicles and of the expres-
sion of certain genes. Significantly lower testosterone
concentrations in serum were detected in rats that
received 0.2 and 0.5 mg PFDoA/kg BW orally per day.
Many factors may play a role in inhibition of testoster-
one by PFDoA since these dosages of PFDoA reduced
levels of the steroidogenic acute regulatory protein, cho-
lesterol side-chain cleavage enzyme, mRNA
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concentrations for insulin-like growth factor I [IGF-I ],
IGF-I-receptor, and interleukin 1a [IL-1a] and altered
genes of the hypothalamic-neurohypophysial system
[205].
The EFSA assumes that thyroid tumors result secon-
darily due to hormone imbalances. It was not possible
to draw a clear conclusion about the mammary gland
tumors. Estradiol-activated growth factors may play a
role in the development of Leydig cell tumors [15].
Immunotoxicity
Yang et al. [206-208] reported on the immunotoxic
potential of PFOA in mice. Addition of a high dose of
0.02% PFOA to the feed for 7 to 10 days led to a loss of
body weight and reduced mass of the thymus and the
spleen. Thymus and spleen cells were reduced by more
than 90% and by approximately 50%, respectively, prob-
ably as a result of inhibition of cell proliferation. The
immature CD4+ and CD8+ populations of the thymus
cells were most noticeably reduced. The T and B cells
were affected in the spleen. An increase in liver weight
and peroxisome proliferation occurred in a similar time
course as the thymus and the spleen atrophy. Exposure
to PFOA (50 to 200 μM) for 24 hours in vitro, however,
had no effect on the thymus and spleen cells [206].
Yang et al. [208] were also able to establish immuno-
suppressive properties of PFOA in in vitro and ex vivo
experiments. Oral administration of PFOA in mice (10
days, 0.02% in feed) inhibited an increase in plaque for-
mation by anti-IgM-IgG as well as an increase in serum
concentration of IgM and IgG that normally occurs
upon immunization with horse red blood cells. An
attenuation of spleen cell proliferation by PFOA was
demonstrated ex vivo. The T- and B-cell activators, lipo-
polysaccharide and concanavalin, serve as triggers for
proliferation of spleen cells; however, no PFOA induced
changes in proliferation were observed in spleen cells in
vitro [208].
Fang et al. [209] discovered toxic effects of PFNA on
the lymphatic organs, T cells, and secretion of cytokines
by lymphocytes in mice. These are likely due to the acti-
vation of PPARa and also PPARg. The hypothalamus-
pitutitary-adreneal axis also appears to play a role since
increased serum concentrations of adrenocorticotropic
hormone and cortisol were detected in exposed mice.
Likewise, cell-cycle arrest and apoptosis were observed
in the spleen and thymus after PFNA exposure [209].
Peden-Adams et al. [210] administered six different
PFOS dosages to mice for 28 days. However, the authors
reported an increase in activity of natural killer cells
only in male mice, and they saw a drop in IgM concen-
tration. Lymphocyte proliferation remained unchanged
in the male and female mice. In this study, it was also
shown that PFOS induces immunotoxic effects at con-
centrations that have also been detected in humans
under special conditions of exposure (serum 91.5 μg/kg;
dose 1.66 μg/kg BW/day). The NOAEL of suppression
of the sheep red blood cell specific IgM production (pla-
que forming cell-response) was 0.166 μg/kg BW/day for
male animals. The PFOS serum concentration at this
dosage was 17.8 ± 4.24 μg/kg. It can be assumed that B
cells are the target location for PFOS-induced immuno-
toxicity [210].
Keil et al. [211] came to similar conclusions in a study
of the immunotoxic effects on the developing immune
system in the F1 generation of exposed mice. The
immunotoxicity of PFOS resulted in functional deficits
in the congenital and humoral immune systems of adult
animals born to mothers that had been orally adminis-
tered 0.1, 1, and 5 mg PFOS/kg/day between the 1st
and 17th day of gestation, a significantly reduced func-
tion of the natural killer cells. A reduced production of
IgM was observed in the F1 generation from the eight
week of life onwards. The male progeny were signifi-
cantly more sensitive to the effects triggered by PFOS
than the female animals [211].
Qazi et al. [212] showed that even a comparatively
short exposure over 10 days with high dosages of PFOS
or PFOA (0.02% in the feed) in mice also suppresses
adaptive immunity and increases the inflammatory reac-
tions to lipopolysaccharides.
In a subsequent study, the authors found that under
the conditions mentioned above, the immune modulat-
ing effects of PFOS are in part the result of PPARa acti-
vation. For example, hepatomegaly (enlargement of the
liver) occurs independently of PPARa; the changes in
the thymus are partially dependent upon PPARa; and
the effects to the spleen are for all practical purposes
eliminated in the absence of the receptors [213]. Further
information on the study by Qazi et al. can be found in
Table 28.
Guruge et al. [214] exposed female mice to 5 or 25 μg
PFOS/kg BW/day for 21 days and then infected them
with influenza virus A/PR/8/34 (H1N1). The mice were
then examined for their defense against influenza A
virus infection. The PFOS concentrations in the blood
plasma, spleen, thymus, and lungs increased clearly after
exposure to the substance (lungs ≈ plasma > spleen ≈
thymus). A significant loss of weight and mortality were
observed as reactions to the virus. Twenty days after
infection, the survival rate of the mice was 46% (control
group), 30% (5 μg/kg BW/day), and 17% (25 μg/kg BW/
day). The average survival time was 14.1 days (control
group), 13.2 days (5 μg/kg BW/day), and 11.4 days (25
μg/kg BW/day). Studies that dealt with immunotoxicity
are presented in Table 28.
DeWitt et al. [215] wrote a summary article on the
immunotoxicity of PFOS and PFOA as well as the role
of PPARa in the process. There is a consensus that
Stahl et al. Environmental Sciences Europe 2011, 23:38
http://www.enveurope.com/content/23/1/38
Page 31 of 52
PFOA and PFOS influence the immune system. The
immune modulation induced by PFOS and PFOA as
observed in animal experiments involve changes in
inflammatory response, production of cytokines and
reduction in weight of the lymphatic organs, and
changes in antibody synthesis. Additionally, there are
indications from experimental studies that PFOA influ-
ences IgE-dependent allergic asthma. Furthermore, the
role of corticosterone in PFOA-induced immunosup-
pression is questioned since the increased corticosterone
concentration is accompanied by reduced IgM antibody
titers, suggesting an immune response triggered by
stress reaction. It was, however, shown by DeWitt et al.
[216] that the suppression of antibody synthesis is not
the result of liver toxicity nor of stress-induced corticos-
terone production.
In addition, it must be noted that different animal spe-
cies show varying degrees of sensitivity to immunologi-
cal effects. It has been shown that certain mouse strains
are the most sensitive animals for immune modulatory
effects of PFOA and PFOS. A few strains already
showed changes at PFOA or PFOS serum concentra-
tions that were about 100 times higher (for PFOA) or
15 times lower (for PFOS) than the concentrations that
had been measured in exposed workers. This indicates
that detailed studies on immunotoxicity in humans are
necessary [215].
Hepatotoxicity and mode of action
Effects on the liver have often been observed in toxico-
logical studies. For example, liver enlargement was seen
in connection with hypertrophy and vacuolization of the
liver cells and an increase in liver weight in studies on










5, 20, and 40 mg/kg
BW/day; 7 days
Food intake, body weight ↓; liver mass, serum
corticosterone concentration ↑; and from 20 mg/kg:
lymphatic cells↓, depression of natural killer cell activity,
lymphocyte proliferation, and antibody forming plasma
cells




8.33, 83.3, 416, 833,
and 2, 083 μg/kg BW/
day; 60 days
From 83.3 μg/kg BW/day: liver mass ↑, altered
lymphocyte proliferation, and activity of natural killer
cells: depression of antibody forming plasma cells
NOAEL: 8.33 μg/kg BW/day, LOAEL: 83.3 μg/kg BW/day
0.674 ± 0.166 mg/L






0.166, 1.66, 3.31, 16.6,
33.1, and 166 μg/kg
BW/day; 28 days
At the three highest dosages: activity of the natural killer
cells ↑ in male mice, altered T cells, and IgM ↓
LOAEL: 1.66 and 16.6 μg/kg BW/day for male or female
animals, respectively
0.092 ± 0.022 mg/kgb







0.005 and 0.025 mg/
kg BW/day
Body weight, immune resistance, and survival rate with
influenza A virus infection ↓
2.1 ± 0.3 mg/L
(control), 189 ± 14 mg/





0.001% to 1% in feed;
10 days
At > 0.02%: clinical effects; at 0.02%: weight ↓,
hepatomegaly, atrophy of the thymus, spleen, and fat
tissue, thymus and spleen cells ↓ by 84% and 43%






7 mg/kg; 28 days Weight gain ↓, liver mass ↑, and no detrimental effects
on the adaptive immune system
11 mg/L Qazi et al.,
[298]
Rat 0.14 to 7.58 mg/kg
BW/day; 28 days
Body weight ↓, liver weight ↑, lymphocyte apoptosis in
the thymus ↑, T helper cells ↑, and B cells ↓
0.4 to 30 mg/kg male








0.02% in feed; 10 days Total number of white blood cells ↓, lymphocyte
number ↓, neutrophilic granulocytes ↓ (only with PFOA),
macrophage number in the bone marrow ↓ (but not in
the spleen or abdominal cavity), and tumor necrosis
factor a and interleukin 6 production ↑ mildly (ex vivo)
340 ± 16 mg/L (PFOS)






0.02% in feed; 7 to 10
days
Body weight ↓, liver mass ↑, spleen and thymus mass ↓,
and peroxisome proliferation ↑




0.02% in feed; 10 days Immunosuppressive: plaque formation ↓, IgM- and IgG
serum concentrations ↓, and proliferation of spleen ↓
n.r. Yang et al.
[208]
Mouse 3.73, 7.5, 15, and 30
mg/kg BW/day; 10
days
T-cell dependent antibody reaction ↓ and no




Mouse 30 mg/kg BW/day; 10
to 15 days




n.r., Not reported; upward arrow, increase; downward arrow, decrease; a50 times higher than that of a human work-related exposure; b14 times lower than that
of an exposed worker; c150 times higher than that of a heavy work exposure or environmentally contaminated human.
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subchronic and chronic toxicity. Most generally, rodents
and nonhuman primates have been exposed to PFCs. In
addition, hepatocellular adenomas occurred in rats.
In particular, liver tumors have been traced to the
activation of PPARa [115]. PPARa occurs primarily in
the liver and can be activated by long-chain polyunsatu-
rated fatty acids or fibrate. As a consequence, there is
an increase in the production of enzymes for fatty acid
recovery, a formation of ketone bodies, and a reduction
in protein synthesis for liponeogenesis [120]. Rats have a
higher susceptibility to the PPARa-based mechanism
than humans. However, hepatocarcinogenicity can also
be only partially attributed to this mechanism. This is
corroborated by the fact that exposure to PFOA also
caused an increase in liver weight in the PPARa knock-
out mice comparable to that in wild-type mice
([15,207,208] cited in BfR [17]). In vitro studies showed
the following:
In Hep G2 cells, PFOA and PFOS (50 to 200 μmol/L)
induced the production of reactive oxygen species
[ROS], the dissipation and/or scattering of the mem-
brane potential of the mitochondria and apoptosis. The
activity of the SOD, catalase, and glutathione reductase
was increased; however, the activity of glutathione-S-
transferase and glutathione peroxidase was lowered. The
glutathione content was reduced. A differential gene
expression was observed after PFC exposure. The
mechanism behind this could be an overload of antioxi-
dative systems, stimulation of ROS formation, an influ-
ence on mitochondria, and interference of gene
expression for apoptosis regulators that initiate the
apoptosis program [217].
In the study by Eriksen et al. [218] on the genotoxic
potential of PFCs in human HepG2 cells, an increase in
intracellular ROS was only detected for PFOS, PFOA,
and PFNA. However, PFOS and PFOA were not found
to cause damage to DNA, and the increase in ROS was
not concentration dependent. PFBS and PFHxA evoked
neither ROS nor DNA damage. Only PFNA led to a
weak increase in DNA damage at cytotoxic concentra-
tions. However, this cannot be accounted for by genera-
tion of ROS [218].
Qian et al. [219] exposed human microvascular
endothelial cells to PFOS. They found that PFOS
induced ROS production in the cells which resulted in a
reorganization of actin filaments and an increased
endothelial permeability.
It must be assumed that PFOS and PFOA can func-
tion as agonists of PPARa. In in vitro experiments,
PFOS activated PPARa [220,221] and led to peroxisome
proliferation, as had been previously shown only in stu-
dies on rodents [108,222,223]. The hepatotoxic effects of
PFOA in studies on rodents may also have resulted
from the activation of peroxisome proliferation
[222-224]. This mechanism is more likely to apply to
PFOA than to PFOS. In a study on rats, a concentration
of 0.64 mg PFOA/kg BW/day and above was found to
induce peroxisome proliferation, clearly illustrating the
effect of PFOA as a PPARa agonist ([141] cited in EFSA
[15]). The activation of PPARa leads to the expression
of genes that are involved in lipid metabolism, energy
homeostasis, cell differentiation, and peroxisome prolif-
eration [225]. This mechanism can result in tumor
induction by non-genotoxic carcinogens.
The fact that the PPARa from mice, rats, and humans
can be activated by PFOS and PFOA was also shown in
a study by Vanden Heuvel et al. [221]. In these experi-
ments, the respective PPAR expression plasmid was
transfected with a luciferase reporter plasmid in mouse
3T3-L1 cells. The relative luciferase activity was mea-
sured after addition of increasing concentrations of pos-
sible PPAR agonists (e.g., 1 to 200 μM PFOA). PFOS
and PFOA had little or no influence on the induction of
PPARb or PPARg. The human PPARa reacted most
strongly, and the rat PPARa, most weakly to PFOS and
PFOA. Compared with the naturally occurring PPAR
ligands, i.e., long-chain fatty acids such as linoleic and
a-linoleic acid, PFOS and PFOA show only a weak
effect on PPAR [221].
Shipley et al. [225] were also able to show the activa-
tion of human and mouse PPARa by PFOS and FOSA.
The test systems used were a COS-1-cell (green monkey
kidney cell)-based luciferase reporter gene transactiva-
tion test and a rat liver cell model. The mean effective
concentration (EC50) was 13 to 15 μM for PFOS with a
little difference between PPARa from mice or humans.
Maloney and Waxman [226], using a similar test sys-
tem, determined the maximum activity of mouse
PPARa by 10 μM PFOA and humans by 20 μM PFOA.
These results were confirmed by a more recent study
using similar methods. PFOS appeared less effective
than PFOA for mice or human PPARa. Neither PFOA
nor PFOS could be shown to have a significant activat-
ing effect on PPARg [227]. In studies using transgenic
mice, Nakamura et al. [228] indicated that the human
PPARa at relatively low concentrations (0.1 or 0.3 mg/
kg) reacts less strongly to PFOA than the mouse
PPARa.
It is also possible that PFCs affect PPARa by changes
in lipid metabolism and transport. The metabolism of
lipids and lipoproteins takes place in part in the liver,
where PPARa is also expressed. Additionally, long-chain
fatty acids are the natural ligands for PPARa. Thus,
Lübker et al. [104] were able to show in vitro that
PFOS, N-EtFOSA, N-EtFOSE, and PFOA could interfere
with the binding affinity of the L-FABP to endogenous
ligands (fatty acids), in the same manner as a strong
peroxisome proliferator.
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The connection between the activation of PPARa by
PFOS and the occurrence of hepatotoxic effects is, how-
ever, unclear since a number of inconsistencies appeared
in regard to the dose-dependent changes. For example,
liver toxicity and hepatocarcinogenicity were seen at
PFOS dosages that were lower than those (200 to 500
mg/kg) that induced peroxisome proliferation in short-
term studies of rats. Stimulation of peroxisome prolif-
eration was not detected in rats with high cumulative
PFOS tissue concentrations. This can likely be explained
by an adaptive downregulation of hepatic peroxisome
proliferation that resulted from PFOS treatment in vivo
[115]. This mechanism also does not seem to be respon-
sible for the observed liver toxicity following PFOS
exposure in monkey. For example, in a study using
cynomolgus monkeys, hypertrophy and lipid vacuoliza-
tion was observed in the group that received 0.75 mg
PFOS/kg/day but without peroxisome proliferation or
increase in palmitoyl-CoA-oxidase activity [128].
In addition, induction of a number of liver enzymes
(carboxylesterase, cytochrome P450, acyl-CoA-oxidase
and -dehydrogenase, as well as carnitine-acetyl-tranfer-
ase) was observed. Reduction of 3-hydroxy-3-methylglu-
taryl-Co A reductase could explain the decrease in
cholesterol and triglyceride concentrations [229]. Gene
expression studies on rat liver cells showed that PFOS
causes changes especially in the genes that play roles in
peroxisomal fatty acid metabolism, hormone regulation,
and transcription of various cytochrome P450 forms
[230].
In regard to PFOA, the correlation of hepatotoxic
effects and activation of PPARa is also not consistent.
For example, in a study on the cynomolgus monkey,
liver mass was seen to increase in association with mito-
chondrial proliferation at the lowest applied dosage (3
mg/kg/day for 26 weeks). The underlying mechanism
could not be explained because the peroxisomal markers
remained unchanged ([146] cited in EFSA [15]). In addi-
tion, the results of another study suggest a PPARa-inde-
pendent mechanism for induction of hepatomegaly by
PFOA in mice. The increase in liver weight correlated
with the exposure to PFOA or a classical peroxisome
proliferator in wild-type mice. This effect did not occur
in the PPARa knockout mice; however, this was only
true for the peroxisome proliferator, not for PFOA. The
hepatomegaly observed in the PPARa knockout mice
could, however, also be the result of an accumulation of
lipid droplets or PFOA in the liver. PFOA also interferes
with lipid and lipoprotein metabolism by activating the
PPARa. The normal lipid metabolism equilibrium in
mammals is disrupted by the induction of enzymes
([230] cited in EFSA [15]). Studies on gene expression
in the rat liver show that exposure to PFOA causes
induction of all genes that are connected with
metabolism and transport of lipids, in particular fatty
acids [230-233]. For example, PPARa activation upregu-
lates a gene that is responsible for the formation of lipid
droplets in many cell types. An increase in the number
of lipid droplets in the liver that resulted from the
changes in lipoprotein metabolism could be detected in
the PPARa knockout mice and might explain the rise in
liver weight after exposure to PFOA [234].
In the study by Minata et al. [235], a 4-week applica-
tion of APFO (12.5, 25, and 50 μmol/kg/day) to PPARa
null mice caused damage to hepatocytes and the bile
duct. In wild-type mice, dosages of 25 and 50 μmol/kg/
day resulted in more severe dose-dependent hepatocel-
lular damage and less striking impairment of the biliary
tract. PPARa null mice that had been exposed to PFOA
exhibited marked fat accumulation, severe damage to
the biliary tract, hepatocellular damage, and apoptotic
cells, most prevalently in the biliary tract. At 50 μmol/
kg/day, the oxidative stress was also increased by a fac-
tor of 4 in these animals; and at 25 μmol/kg/day, TNF-
a mRNA was upregulated by a factor of 3. The bile
acid/phospholipid ratio was higher in these animals than
that in wild-type mice. These results suggest that
PPARa may actually protect against effects of PFOA
and plays a critical role in xenobiotic-induced hepato-
biliary damage [235].
A further study by Elcombe et al. [236] indicates that
PFOA possesses the properties of a mixed enzyme indu-
cer. It induces various cytochrome P450 types in liver
microsomes. This induction profile implies a reaction of
PFOA with various receptors of the super family of
nuclear hormone receptors, in particular with PPARa,
constitutive androstane receptor [CAR], and pregnane-X
receptor [PXR ] [236]. Ren et al. [237] were able to
show the activation of PPARa, CAR, and PXR by PFCs
in rats, but not in chickens or fish. Furthermore, the
PFOS-induced gap junctional intercellular communica-
tion [GJIC] and in vivo (GJIC) inhibition observed in
vitro in the rat liver may be of importance in liver carci-
nogenesis [115,238]. This process is used by cells to
exchange ions, secondary messengers, and other small
molecules. In multicellular organisms, GJIC plays a role
in tissue homeostasis, normal growth, development, and
differentiation. An in vitro study by Upham et al. [239]
showed a dysregulation of GJIC by PFOA that resulted
from the activation of the extracellular receptor kinase
and phosphatidylcholine specific phospholipase. This
evidence suggests that PFOA may also have an effect on
GJIC in vivo. Inhibition of GJIC appears to only be a
property of PF with a chain length of 7 to 10 carbon
atoms. For example, PFPeA did not exhibit inhibitory
effects on GJIC and did not cause hepatomegaly [239].
The meaning of this widespread and reversible mechan-
ism in carcinogenesis of PFOS or PFOA is, however,
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still unclear [15,115,185]. Experiments on the impor-
tance of the length of the carbon chain of different
PFCs for liver toxicity and peroxisome proliferation in
mice and rats suggest that longer chain molecules are
more toxic due to their accumulation in the liver
[115,240-242].
Combination effects
Wei et al. [243] studied the combined action of PFCs
(PFOA, PFNA, PFDA, PFDoA, PFOS, 8:2 FTOH at a
concentration of 5 mg/L each). The authors created a
gene expression profile using a DNA microarray to detect
changes in cultivated hepatocytes from minnows. The
fish were treated with four mixtures of these substances
or with each substance individually. The study showed
that, in fact, certain genes were regulated by the mixture
that were unaffected by the individual substances. The
effected genes are involved in fatty acid metabolism and
transport, in xenobiotic metabolism, in the immune
response, and in the emergence of oxidative stress [243].
In another study exposure to a mixture of PFOS and
PFOA (50 to 200 μmol/L each) induced and expedited
cell apoptosis more effectively than did exposure to the
individual substances. This suggests summation effects
that, however, appear to be neither synergistic nor antag-
onistic. Therefore, the effect on the cells was stronger
with the mixture than with PFOS or PFOA alone [217].
Using a micronuclear test, Jernbro et al. [244] investi-
gated whether the presence of PFOS increased the geno-
toxic potential of cyclophosphamide [CPP] in hamster
V79 lung cells. Up to a concentration of 12.5 μg/mL
PFOS did not show any genotoxic effects. However,
after metabolic activation, a combination of PFOS and
two different dosages of CPP (1.25 and 2.5 μg/mL)
resulted in a greater number of micronucleus containing
cells than in cells treated with CPP alone. PFOS induced
changes to the cell membrane, and the ensuing changes
in the uptake of toxic substances may play a role in
these observations [244].
Watanabe et al. [245] examined the effect of co-expo-
sure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin 2, 3, 7, 8-
[TCDD] and PFOS or PFOA on expression of cyto-
chrome P450 isoforms (monooxygenases) in a chicken
embryo hepatocyte culture. PFOS or TCDD alone did
not induce mRNA production of CYP4V2; however,
administration of 40 to 50 μM PFOS plus 0.3 nM
TCDD did. A combination of TCDD and PFOA
behaved exactly the same way. PFOS caused an increase
in CYP1A4 mRNA with or without TCDD co-exposure.
The authors suspect a complex gene response to the
combined exposure of multiple xenobiotics [245].
Epidemiological studies
Epidemiological studies have been primarily carried out
on groups of people who are occupationally exposed to
PFCs. These took place, for example, in the course of
medical monitoring studies of workers in the fluoro-
chemical industry. The workers were principally from
the PFC manufacturing company, 3M, in Decatur, Ala-
bama, USA and Antwerp, Belgium. In particular, bio-
chemical parameters for liver damage or interference
with lipid metabolism were examined. Furthermore,
hormonal changes and cancer death rates and/or tumor
incidence were at the center of interest. Recent studies
have also examined possible reproductive toxicities. The
significance of these epidemiological studies is, however,
limited because of the small number of participants,
mostly males due to the working structure in the com-
panies, and the problematic classification of exposure
[17,115].
Studies on biochemical parameters and mortality rates
An epidemiological study was carried out on 2, 083
workers in a factory in Decatur in which perfluorooctane
sulfonylfluoride [POSF] is manufactured and processed.
The workers had been employed for at least one year in
the company and had been exposed to POSF-based
materials by inhalation, skin contact, and/or ingestion.
The various workplaces were categorized according to
the amount of exposure as determined by analysis of
serum samples of the individual workers. A total of 982
people (47%) were subjected to a relatively high POSF
exposure at their workplaces. The proportion of males in
this subcohort was 84%. Of a total of 145 deaths, 65
(45%) were of these workers with high PFOS serum con-
centrations (ca. 0.6 to 2 mg/L). This group had a risk of
urinary bladder cancer 13 times higher than did the gen-
eral population of Alabama. This is based on three deaths
compared to 0.23 expected cases of bladder cancer (stan-
dard mortality rate [SMR] = 12.8). The workers with can-
cer carried out maintenance work in the factory and
worked in the area of the incinerator and sewage treat-
ment plant. It is, however, possible that the workers were
also exposed to other bladder cancer-producing com-
pounds outside of the workplace. Other mortality rates in
this study were below the statistically expected number of
deaths. For example, there were five cases of liver cirrho-
sis among the total number of participants (SMR 0.85).
In animal experiments, however, the liver was identified
as the target organ of PFCs [15,246].
In the follow-up study, 11 cases of bladder cancer
were documented among the total of 1, 588 participants.
Eight cases would be expected statistically. Three of the
bladder cancer victims had worked for more than a year
at jobs with high PFOS exposure (mean serum concen-
tration 1.3 to 1.97 mg/L). Nonetheless, the correlation
between PFOS exposure and increased risk of bladder
cancer was not significant [247].
Grice et al. [248] were unable to detect an association
between occupational PFOS exposure and the
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occurrence of skin, breast, prostate, or intestinal cancer
in workers at a PFC-producing company. In addition,
there was no correlation between PFOS exposure and
the state of health or the course of pregnancies and
birth weight. This study was undertaken with the use of
questionnaires and medical reports and, as in the study
by Alexander et al. [246], encompassed 2, 083 workers
of a POSF-processing factory in Decatur [248].
The first retrospective cohort study on mortality of
employees of the PFOA-producing factory of 3 M was
carried out by Gilliland and Mandel [249]. Participants
in the study (2, 788 men and 749 women) were required
to have worked for at least 6 months in the factory
between 1947 and 1983. In this time period, 398 work-
ers died (348 men and 50 women). Eleven and 148 of
the deceased women and men, respectively, had been
exposed to APFO. The SMR for prostate cancer (2.03)
was increased, based on four deaths out of 148 cases of
APFO-exposed workers. The expected frequency would
have been 1.97. The relative prostate cancer risk for a
one year longer period of employments was 1.13 and
rose to 3.3 for workers who had been employed there
for over 10 years. The SMR value for other causes of
death was not significantly increased [249].
An update of this study was undertaken by Alexander
[250] in order to record the deaths that occurred by
1997. The 3, 992 employees were divided into three
exposure categories: definite exposure, possible expo-
sure, and exposure not expected. The 607 deaths were
allocated to these three categories (46, 267, 294).
Regarding all workers, the highest SMR (1.31) was for
bladder cancer. A few of the SMR values were elevated
in the group that was definitely exposed. For example,
two deaths resulted from colon cancer (SMR 1.67), one
from pancreatic cancer (SMR 1.34), and one from pros-
tate cancer (SMR 1.3). In the group with possible expo-
sure, elevated SMR values were obtained for cancers of
male sexual organs (2.75), pancreas (1.24), and skin
(1.42). The results are difficult to interpret because of
the changing, more specific exposure categories. The
previously determined significant association between
prostate cancer and time of employment could not be
confirmed in this study [15].
A recent epidemiological study was undertaken by
Lundin et al. [251]. The authors examined the correla-
tion between the APFO exposure of 3, 993 workers in
the 3 M factory in Minnesota and the rates of mortality.
This study differed from that of Gilliland and Mandel
[249] because of newer data and increased exclusion of
workers with only short times of exposure. The workers
were divided into three exposure categories: definite
exposure, possible exposure, and workplace without
exposure. APFO exposure was not associated with liver,
pancreas, or testicular cancer but presumably with
prostate cancer, cerebral vascular disease, and diabetes
mellitus [251].
Studies by DuPont [252] provide little information
about correlations of PFOA exposure at the workplace
and death rates or incidence of cancer since data on
exposure, contact with other substances, and lifestyle
were missing. Significant differences regarding exposure
were shown for bladder and kidney cancer [15,115]. A
subsequent study indicated increased SMR values for
kidney, liver, and bladder cancers; however, the only sig-
nificant increase in rate of death was from diabetes mel-
litus ([253] cited in Lau et al. [115]). No significant liver
toxicity was found in a further study by Gilliland and
Mandel [254] of 115 males, occupationally PFOA-
exposed study participants with PFOA serum concentra-
tions of (0 to 26 mg/L; mean 3.3 mg/L), although hepa-
totoxic effects often occurred in studies of rats. Total
fluorine values were measured since 90% of those in
serum are made up of PFOA. The enzymes of the liver
(serum glutamate oxaloacetate transaminase, serum glu-
tamate pyruvate transaminase, gamma glutamyltransfer-
ase), the lipoproteins (LDL, HDL), and the cholesterol
values were within the normal zone of fluctuation. Pos-
sible disturbance variables such as body mass index
[BMI] and tobacco and alcohol consumption were taken
into account. Based on the enzyme profiles, the authors
suspected that PFOA possibly modulates the reaction of
the liver to obesity and xenobiotics [254].
Olsen et al. [68] examined similar parameters in con-
nection with the PFOS serum concentrations in workers
involved in the production of fluororganic compounds
at 3 M. In 1995, the PFOS mean concentration for 178
male workers was 2.19 mg/L, and in 1997, the concen-
tration for 149 workers was 1.75 mg/L. No explicit
changes in liver enzymes, cholesterol, or lipoproteins in
serum could be detected in the serum of workers with
PFOS concentrations below 6 mg/L [68].
One year later, a study was published by Olsen et al.
[255] on workers in the production of APFO. The mean
PFOA serum concentration was 5 mg/L (1993), 6.8 mg/
L (1995), and 6.4 mg/L (1997). Cholecystokinin concen-
tration in plasma was also determined. It was assumed
that pancreatic adenomas of the acinar cells observed in
animal studies were caused by a steady increase in cho-
lecystokinin that resulted from hepatic cholestasis (bile
congestion). However, the cholecystokinin values (aver-
age 28.5 ng/L) were within the reference range and were
negatively coordinated with increasing PFOA concentra-
tions. The measured PFOA concentrations, therefore,
did not appear to cause a hepatotoxic effect. The pre-
vious suspicion that PFOA modulates the reaction of
the liver to obesity and alcohol consumption could not
be confirmed. The weak points in the study were the
small number of workers (17), the relevant experimental
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data for whom encompassed only three years, the low
rate of participation in the study (50% to 70%), and the
low number of participants with serum concentrations
over 10 mg/L [255].
Olsen et al. [69] then linked PFOS and PFOA serum
concentrations with data from medical examinations of
workers in one plant. The mean serum concentrations
of PFOS and PFOA of the 263 workers in Decatur were
found to be 1.32 mg/L and 1.78 mg/L, respectively. The
serum concentrations of the 255 workers at the plant in
Antwerp were approximately 50% lower. After taking
into consideration possible disturbance variables (age,
BMI, cigarette, and alcohol consumption per day) no
conspicuous changes in the blood, lipid, liver, thyroid,
or urine parameters were noted [69].
Possible weak points in the study of Olsen et al. [69]
were taken into consideration in a following study by
Olsen and Zobel [256]. Since the intention was to mea-
sure cholesterol levels, persons who took cholesterol-
lowering drugs were excluded. The calculations of LDL
were not coupled to triglyceride values, and data on
PFOA were also gathered both in Antwerp and Decatur.
The study comprised 506 workers at 3 M factories in
Antwerp, Minnesota and Alabama who took part in a
‘fluorochemical medical surveillance program.’ PFOA
serum concentrations were between 0.007 and 92.0 mg/
L. The total cholesterol or LDL concentrations were not
significantly altered with increasing PFOA concentra-
tions in the serum after removal of the disturbance vari-
ables such as age, BMI, and alcohol consumption (P >
0.05). HDL was negatively correlated with PFOA in the
workers at all three locations, but not in employees at
each individual location. This may be explained by
demographic differences between the locations. The
positive correlation of triglyceride values with PFOA
serum concentrations of the workers appeared similar.
There was no statistically significant correlation between
the concentrations of PFOA and liver enzyme activities.
Only for the employees at one of the locations was a
weak positive association apparent. Results were incon-
sistent for thyroid hormones. TSH and T4 concentra-
tions showed no correlation to PFOA levels. Free T4
was negatively associated to PFOA, whereby increases in
T3 concentrations were correlated with increased PFOA
values. Nonetheless, thyroid hormone levels were within
the range of reference values [132].
Olsen et al. [257] looked for potential correlations
between PFOA exposure and changes in hormone levels
in male PFOA production workers. The focus of the
study was on a drop in T3 and T4 levels and estrogen-
like effects. The study showed an increase in mean
estradiol concentration of approximately 10% at the
highest PFOA serum concentrations (> 0.03 mg/L) in
the 191 workers. This relationship, however, could have
been influenced by the BMI. No PFOA concentration
relationships were found for other hormones. The weak
points in this study were the cross-sectional design that
led to the low number of participants with high blood
PFOA concentrations [257].
In regard to blood lipids, liver enzymes, and occupa-
tional exposure to APFO, Sakr et al. [258] detected an
increase in total cholesterol (10.6 mg/L per 1 mg/L
PFOA) and aspartate aminotransferase (0.35 U per 1
mg/L PFOA) in serum. After adjusting for possible
influencing factors, an association of PFOA concentra-
tions and triglyceride or lipoprotein levels was no longer
recognizable. Total bilirubin was reduced by 0.08 mg/L
per 1 mg PFOA/L serum in exposed persons.
Because of the correlation between APFO exposure
and increased lipid concentrations in serum, Sakr et al.
[259] examined the association of APFO exposure and
incidence of ischemic heart disease. The study cohort
comprised 4, 747 workers from the DuPont Washington
Works. However, no evidence was found of an increased
mortality risk for ischemic heart disease in the exposed
workers [259].
Costa et al. [260] evaluated medical surveillance
reports for the years 1978 to 2007 from workers who
had been employed in the PFOA-producing industry.
The study population comprised 53 male workers who
had received a medical examination each year and for
whom blood tests for various parameters and for PFOA
concentrations were available. In the most recent study
from 2007, the PFOA concentrations of workers pre-
sently employed were 0.2 to 47 mg/L (mean value 5.71
mg/L), and for previously exposed workers, 0.53 to 18.7
mg/L (mean value 4.43 mg/L). No clinical evidence was
found to indicate a correlation between PFOA concen-
trations and illness in the 30 years of observation. Bio-
chemical parameters for liver, kidneys, and hormonal
functionality were also within the reference range. How-
ever, significant correlations between the PFOA serum
concentration and the total cholesterol and uric acid
levels were detected, as had also been previously
reported by Sakr et al. [258]. This is suggestive of an
effect of PFOA on purine metabolism in the liver [260].
Very few epidemiological studies exist with data from
the general population. In a study by Bloom et al. [261],
they compared concentrations of various PFCs (PFDA,
PFNA, PFHpA, PFHxS, PFOA, PFOS, FOSA, PFUnA) as
well as free T4 [FT4] in the blood of 31 fishermen from
New York. The background of this study is the crucial
role played by the thyroid hormones in the neuronal
development of human beings. A statistically significant
correlation was not found between any of the PFCs
examined or the sum of all the substances and TSH or
FT4 concentration. There is a possibility, however, that
a weakly positive correlation exists between FT4, PFDA,
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and PFUnA, detected in low concentrations (0.21 and
0.2 μg/L) in the blood of the fishermen.
Based on possible effects of PFCs on the thyroid, Pirali
et al. [262] examined PFOS and PFOA in surgical thyr-
oid samples from patients with diseases of the thyroid.
The substances were detected in all samples. The mean
concentration for PFOS was 5.3 μg/kg, and for PFOA,
2.0 μg/kg. There was no correlation between the
intrathyroidal PFC concentrations and the occurrence of
thyroid diseases. For PFOS, a correlation between the
tissue and serum concentrations was established. The
serum concentrations were always higher than the
respective surgical tissue samples.
Melzer et al. [263] also investigated a correlation
between the occurrence of thyroid diseases and PFOS
and PFOA in 3, 974 adults from the NHANES. The
authors came to the conclusion that higher PFOA and
PFOS serum concentrations were associated with a thyr-
oid disease in adults of the general US population. More
women with blood concentrations of ≥5.7 μg PFOA/L
were found to have currently treated thyroid disease
than women with ≤ 4.0 g/L of blood levels. More men
with blood concentrations of PFOS ≥36.8 μg/L also had
diseases of the thyroid than men with concentrations ≤
25.5 μg/L. The correlation with PFOS in women was
not significant [263].
Test persons from the general public that had been
contaminated with higher concentrations of PFOAf in
drinking water had distinctly higher serum values (mean
354 μg/L) than the average population in the US (mean
4 to 5 μg/L). A blood count was made; biochemical
parameters were recorded; and the subjects were inter-
viewed. No statistically significant correlations could be
found between the PFOA serum concentration and the
values from liver and kidney tests, or with cholesterol or
TSH concentrations in serum or with the blood count
in regard to red or white blood cells or thrombocytes
when compared to standard reference values from the
general population. PFOA concentrations were not ele-
vated in persons with liver or thyroid illnesses ([264]
cited in BfR [17]).
Nelson et al. [265] established a positive association
between PFOS, PFOA, and PFNA and total cholesterol,
LDL, and very LDL [VLDL] levels. The participants
from the highest PFOS quartile (44.8 ± 28.0 μg/L) had
13.4 mg/dL higher total cholesterol concentrations than
the participants from the lowest quartile (9.6 ± 2.9 μg/
L). The differences were 9.8, 13.9, and -7.0 mg/dL for
PFOA, PFNA, and PFHxA. Thus, an opposite result was
detected for PFHxS. The authors did not find any corre-
lations between PFC concentrations and BMI, hip mea-
surent, or insulin resistance.
Steenland et al. [266] also detected increased blood-
lipid levels in connection with elevated PFOA and PFOS
concentrations in the blood. HDL was the only excep-
tion to this.
The study comprised 46, 294 persons who had been
residents for more than 18 years and who drank water
contaminated with PFOA by a chemical factory in West
Virginia. The mean PFOA and PFOS serum concentra-
tions were found to be 80 μg/L and 22 μg/L. The cho-
lesterol level increased from 11 to 12 mg/dL, from the
lowest to the highest decile for both substances.
Elevated PFOA serum concentrations were also asso-
ciated with a higher prevalence of hyperuricemia. The
uric acid level increased by 0.2 to 0.3 mg/dL, from the
lowest to the highest decile of PFOA or PFOS concen-
tration [267].
Anderson-Mahoney et al. [268] examined 566 persons
who also had been exposed to PFOA via drinking
waterg. In a questionnaire, the participants were asked
about their medical anamnesis. There was evidence that
exposed persons more often suffered from angina, myo-
cardial infarctions, chronic bronchitis, shortness of
breath, and asthma. Further studies will be necessary to
determine whether PFOA is the cause of the increased
prevalence of these effects in PFOA-exposed persons
[268].
Additionally, Lin et al. [269] showed a correlation
between PFCs and glucose homeostasis, as well as other
indicators of metabolic syndrome. In the general popu-
lation, elevated PFNA serum concentrations were asso-
ciated with hyperglycemia, correlated positively with
HDL levels in serum, and correlated inversely with the
prevalence of metabolic syndrome. Increasing PFOA
serum concentrations increased the b-cell function. Ele-
vated PFOS serum concentrations increased the insulin
level in the blood, insulin resistance, and b-cell function
and was negatively correlated with serum HDL choles-
terol values [269].
McNeil et al. [270] pursued the results of a study that
established an increased diabetes mortality rate in
PFOA-exposed workers. Based on 22 diabetes deaths,
employees of the Washington Works exhibited twice
the mortality rate over other non-exposed workers
[271]. The study population (n = 54, 468) comprised
participants in the C8 health project. A total of 1, 055
people had type II diabetes and before diagnosis, had
lived in the area of elevated PFOA contamination, most
likely the result of contaminated drinking water. The
PFOA serum concentration for these individuals was
found to be 0.028 mg/L (mean) in contrast to 0.004 mg/
L for the general population of the USA. Table 29 lists
the PFOA serum concentrations of the participants in
this study.
Diabetes prevalence amounted to 7.8%. A decreasing
risk of diabetes was found for the highest PFOA serum
concentration compared with the lower values, but
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without showing a consistent negative correlation. Tak-
ing age into account, however, this correlation could be
reversed. A consistent pattern was not apparent for fast-
ing serum glucose levels in connection with PFOA
serum concentrations. Consequently, an unambiguous
trend for diabetes risk in connection with PFOA serum
concentrations did not emerge. However, a correlation
cannot be dismissed on the basis of the results of this
study since the data was limited due to the cross-sec-
tional design, and a causal relationship cannot be
excluded. For these reasons, the authors are planning
further studies with an improved design [270]. The stu-
dies listed in the ‘Studies on biochemical parameters
and mortality rates’ section are summarized in Table 30.
The US EPA also discussed existing epidemiological
studies in 2005. Nevertheless, a consistent correlation
between PFOS, PFOA, or APFO serum concentrations
in humans and adverse health effects could not be
observed.
According to the German BfR [17], only a few indivi-
dual studies have shown statistically significant relation-
ships between the concentration of liver enzymes,
cholesterol level, HDL concentration, and triglyceride
concentration or concentration of individual hormones
in the human blood and the exposure to PFCs. In addi-
tion, the correlations could generally not be confirmed
in subsequent studies and even contradicted the effects
of the compounds observed in animal experiments [17].
More recent studies indicate correlations between PFC
concentrations and diabetes and thyroid disease, as well
as blood lipid and uric acid levels; however, these can-
not be considered proven and will need to be confirmed
in further studies.
Studies on reproductive and developmental toxicity
Grice et al. [248], in a written survey on exposure and
the course of pregnancy, comprising 421 women who
had been occupationally exposed to PFOS, did not find
a correlation between the degree of PFOS exposure and
birth weight of the children. One of the first studies
published that analyzed the PFC concentration in the
maternal blood and cord blood as parameters for the
exposure of the fetus and/or newborn stemmed from
Inoue et al. [54]. The authors examined 15 mother/child
pairs in Japan and did not find a correlation between
PFOS in the cord blood and birth weight or
concentration of thyroid hormones in the blood of the
newborn. This may well be the consequence of the con-
centrations to be expected in cord blood and the rela-
tively high limit of detection, 0.5 μg/L [54].
In the study by Fei et al. [57], 1, 400 selected mother/
child pairs from the Danish ‘National Birth Cohort’ were
examined in an attempt to find possible correlations
between the concentration of PFOS and PFOA in the
maternal blood during the first and second trimesters of
pregnancy and the birth weight and risk of premature
birth. A correlation between PFC concentration in the
maternal plasma and birth weight of children from
mothers of normal weight could only be shown for
PFOA. The length of gestation was unrelated to PFOS
or PFOA concentrations in the maternal blood [57].
Monroy et al. [56] also measured the PFC concentra-
tion in the blood of pregnant women in the 24th to the
28th week, at birth, and in the cord blood. PFOS and
PFOA were detected in all samples. Also in this study,
the PFOS serum concentrations were higher during
gestation (18 ± 11 μg/L) than at the time of birth (16 ±
10 μg/L) and higher than in the cord blood (7.3 ± 5.8
μg/L). The differences were smaller for PFOA (24th to
the 28th week of gestation 2.5 ± 1.7 μg/L; birth 2.2 ±
1.6 μg/L; cord blood 1.9 ± 1.5 μg/L). PFHxS was
detected in 45.5% of the maternal samples and in 20%
of the cord blood samples [56].
On the other hand, in a cross-sectional study, Apel-
berg et al. [55] found a weak inverse correlation between
the concentration of PFOS and PFOA in the cord blood
and birth weight, the ponderal index, and head circum-
ference of 293 newborns. No correlation was found
between the concentration of the substances and the
birth length or gestation time. The results for birth
weight were statistically corrected for influence factors
such as the mother’s smoking habits, diabetes, and
hypertension. The authors recommend exercising cau-
tion when interpreting these results since the association
of head circumference was only for vaginal births; the
newborns were all healthy, and the variations in head
circumference and birth weight were within the normal
range [55]. Washino et al. [272] could also see a nega-
tive correlation between the in utero PFOS exposure
and the birth weight of baby girls. A correlation between
the PFOA concentration and the birth weight was not





(n = 54, 468)
Self-reported type II
diabetes (n = 4, 278)
Diagnosed type II
diabetes (n = 3, 539)
Long-standinga resident with type II diabetes
diagnosed in the last 10 years (n = 1, 055)
Mean 0.087 0.093 0.091 0.123
Median 0.028 0.030 0.033 0.049
Geometric mean 0.033 0.034 0.036 0.052
aAt least 10 years in a region with elevated PFOA contamination.
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Table 30 Epidemiological studies on biochemical parameters and mortality rates of humans related to PFC exposure







2, 083 Workers in POSF production (USA);
minimal time of employment is one year
Heavy-exposure group: deaths resulting from
bladder cancer, 3; SMR, 12.8; and no increase in
liver disease
PFOS, ca. 0.6 to 2 (GM) Alexander
et al. [246]
Workers in POSF production (USA), 1, 400
questionnaires, and 188 death certificates
11 Cases of bladder cancer and 8 expected PFOS, ca. 1.3 to 1.97 Alexander
and Olsen
[247]
Workers in POSF production (USA); 1, 400
questionnaires
No association between PFOS and various forms of
cancer, and no correlation between PFOS
contamination and state of health, course of
pregnancy, or birth weight
PFOS, ca. 0.1 to 1.97 Grice et al.
[248]
3, 537 Workers in POSF production (USA) Elevated SMR for prostate cancer (2.03) and no






3, 992 Workers All workers: elevated SMR for bladder cancer, 1.31;
group with certain exposure: elevated SMR for
colon, pancreas, and prostate cancers
n.r. Alexander
[250]
4, 747 Workers No clear evidence of increased risk of death that
resulted from ischemic heart disease
n.r. Sakr et al.
[259]
3, 993 Workers of the 3 M plant (USA) No association with liver, pancreas, and testicular
cancer and liver cirrhosis; elevated SMR for
prostate cancer, cerebrovascular diseases, and
diabetes
Certain APFO exposure
is 2.5 to 5.2; possible






191 Workers, 111 in 1993 and 80 in 1995
(USA)
Increase (10%) in estradiol level at > 0.03 μg/mL
PFOA (BMI as cofactor); for other hormones: no
association with PFOA serum concentration






115 male workers (USA) As related to enzymes in the liver, lipoproteins,
and cholesterol, no significant indication of liver
toxicity or dysfunction
Total fluorine






178 Male workers in 1995 and 149
workers in 1997
No dramatic changes in liver enzymes, cholesterol,
or lipoproteins in serum
PFOS, < 6 Olsen et
al. [68]
111 Male workers (1993), 80 male workers
(1995), and 74 male workers (1997) in
APFO-production
No changes in hepatic enzymes, cholesterol, or
liporotein levels
PFOA 5 (1993), 6.8
(1995), and 6.4 (1997)
Olsen et
al. [255]
263 Workers of the 3 M factory in Decatur
(USA) and 255 workers from the plant in
Antwerp (Belgium)
No conspicuous changes in blood, liver, thyroid, or
urinary parameters after correcting for possible
interfering factors
Decatur: PFOS, 1.32 and




506 Workers in the three 3 M factories in
Antwerp, Minnesota, and Alabama
No significant correlation of PFOA with total
cholesterol or LDL concentrations, liver enzymes,
TSH, and T4; inconsistent results for HDL and
triglyceride values; FT4 was negatively correlated
with PFOA; and T3 elevation with increasing PFOA
concentrations ® within reference values





454 Workers with APFO exposure (USA) Elevation of total cholesterol and AST levels; no
correlation with triglycerides or lipoproteins
n.r. Skar et al.
[258]
53 Male workers, from 1978 to 2007 No clinical evidence of dysfunction or disease;
biochemical parameters for liver, kidneys, and
hormonal functionality within reference values; and
significant correlation between PFOA serum
concentration and total cholesterol and uric acid
levels
PFOA is 0.2 to 47.04




371 Persons of the general public that
were exposed to PFOA via drinking water
No significant correlation of PFOA concentration
with liver or kidney function tests, cholesterol
levels, TSH hormone level, or values for various
blood cells




Participants in the NHANES study 2003/
2004 between 12 to 80 years of age
Positive association between PFOS, PFOA, and
PFNA and total cholesterol, LDL, and VLDL levels
for PFHxS, a negative correlation
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found. Hamm et al. [273] were unable to establish an
association between the birth weight or gestation time
and the maternal serum concentrations (mean values:
PFOA 1.5 μg/L, PFHxS 0.97 μg/L, PFOS 7.8 μg/L).
Nolan et al. [274] investigated the relationship between
a PFOA-contaminated drinking water supply and the
birth weight and gestation time. They did not find any
indication for low birth weight or premature birth
related to the water supply. The risk group comprised
mothers from Washington County, Ohio. The drinking
water there had a PFOA concentration 80 times higher
(6.8 μg/L) than can be assumed for the general US
population [274]. More recent studies by the authors,
also dealing with the connections between the PFOA
contamination of drinking water (customers of the Little
Hocking Water Association) and the pregnancy compli-
cations, indicate an association of PFOA exposure, the
incidence of anemia, and dysfunction of labor contrac-
tions [275].
Stein et al. [276] also described a connection between
PFOA and PFOS serum concentrations of residents of
the Mid-Ohio Valley (200 to 2, 006) who were exposed
to PFOA in drinking water with self-reported courses-
of-pregnancy descriptions. PFOA measurements for 1,
845 pregnant women and PFOS values for 5, 262 preg-
nant women were available. The mean PFOA concentra-
tion in serum was 49 μg/L, and the mean PFOS
concentration was 15 μg/L. Neither the PFOS nor
PFOA serum concentrations could be statistically corre-
lated with miscarriage or premature birth. However, a
weak association of PFOA with the development of pre-
eclampsia and congenital defectsh was noted. A weak
connection was also shown for PFOS and development
of preeclampsia. Mean PFOS concentrations exceeding
12.8 μg/L were seen to increase the risk of reduced
birth weight of newborns. It must be noted, however,
that these associations were weak and imprecise and
were based solely on reports made by the pregnant
women [276].
Fei et al. [277] investigated the development of infants
with the help of questionnaires that the mothers were to
fill out when their children were between 6 and 18 months
of age. These data were examined in connection with pre-
natal exposure to PFOA and PFOS. The authors could not
find any differences in the development of the infants
from mothers with high PFOA and PFOS blood concen-
trations (PFOA 7 to 42 μg/L; PFOS 43 to 107 μg/L) and
children of mothers with low PFOA and PFOS blood con-
centrations (PFOA < 1 to 4 μg/L; PFOS 6 to 26 μg/L). The
Apgar scores and point in time of developmental progress
were similar for children of mothers with high PFOS and
PFOA concentrations in blood as for children of mothers
with low PFOS and PFOA blood concentrations. There
was only a weak indication that children of mothers with
high blood concentrations of PFOS began to sit without
support at a later time point [277].
A further study by Fei et al. [278] suggests a possible
impairment of fertility as seen in the PFOS and PFOA
blood concentrations measured in the general popula-
tion. The mean PFOS and PFOA plasma concentrations
of women who planned to get pregnant were 33.7 μg/L
and 5.3 μg/L, respectively. The time until pregnancy was
longer in the proband group with higher PFOA and
PFOS contaminations [278].
Since PFOA was seen to cause impairment of lactation in
mice, Fei et al. [279] examined PFOS and PFOA
Table 30 Epidemiological studies on biochemical parameters and mortality rates of humans related to PFC exposure
(Continued)
46, 294 Residents for more than 18 years
that drank water contaminated with
PFOA by a chemical factory in West
Virginia
Rising blood lipid values with increasing PFOA and
PFOS concentrations in the blood
PFOA, 0.080; PFOS, 0.022 Steenland
et al. [266]
54, 951 Adult residents from Ohio and
West Virginia exposed via drinking water
Elevated uric acid concentrations in the highest
decile of PFOA or PFOS concentrations compared
with the lowest
PFOA, 0.189; PFOS, 0.041 Steenland
et al. [267]
Disease 566 Persons exposed to PFOA via
drinking water
Increased occurrence of angina, myocardial





General public comprising 474 adults and
969 juveniles in Taiwan
Correlation of PFCs with glucose homeostasis and
other indicators of the metabolic syndrome
n.r. Lin et al.
[269]
54, 468 Persons exposed to PFOA via
drinking water, 1, 055 with type II
diabetes
Reduced risk of diabetes mortality at high PFOA
values; not consistent
PFOA, 0.028 McNeil et
al. [270]
28 Patients who had had thyroid
operations
No correlation between intrathyroidal PFC
concentrations and occurrence of thyroid disease
n.r. Pirali et al.
[262]
3, 974 Adults of the NHANES study High PFOA and PFOS serum concentrations





n.r., Not reported; GM, geometric mean.
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concentrations in connection with duration of nursing in 1,
400 nursing women. They discovered a decrease in dura-
tion of nursing in correlation with increasing PFC concen-
trations by women who had had repeated births. Whether
PFOS or PFOA really reduces the ability to nurse or
whether the correlation is reversed remains questionable.
Hoffman et al. [280] discovered an increasing risk of
attention deficit hyperactivity disorder [ADHD] in chil-
dren with elevated PFC serum concentrations. Data
from the NHANES study from 1999 to 2000 and from
2003 to 2004 on ADHD and PFC blood concentrations
from 571 children between the ages of 12 and 17 were
evaluated in this study. Forty eight children were
reported to suffer from ADHD. The corrected odds
ratios for an increase of 1 μg/L serum concentration of
PFOS, PFOA, PFHxA, and PFNA were 1.03, 1.12, 1.06,
and 1.32, respectively. The results of epidemiological
studies on the correlation between PFC blood concen-
tration and reproduction and developmental toxic
effects are summarized in Table 31.
Olsen et al. [281] published a review article on epide-
miological studies that dealt with the influence of PFCs
Table 31 Results of studies on reproduction toxicological effects of PFCs on humans
Effects Study population Results Reference
Birth weight Occupationally exposed women, USA No correlation between extent of PFOS exposure and birth weight Grice et
al. [248]




General population, Danish National Cohort Correlation between the PFOA concentration in mother’s plasma
and birth weight; not detectable for PFOS
Fei et al.
[57]
General population, USA Weak inverse correlation between concentrations of PFOS and
PFOA in cord blood and birth weight
Apelberg
et al. [55]
General population, Canada No correlation of PFC serum concentrations and birth weight Monroy et
al. [56]
General population, Japan, 2002 to 2005 Negative correlation of in utero exposure to PFOS birth weight;
not detectable for PFOA
Washino
et al. [272]














General population, Danish National Cohort No correlation of PFOA and PFOS concentrations in mother’s
plasma with time of gestation
Fei et al.
[57]
General population, USA No indication of premature birth as a result of PFOA
contamination via drinking water
Nolan et
al. [274]
General population, USA, 2000 to 2006 No connection of PFOS or PFOA serum concentration with
miscarriage or premature birth
Stein et al.
[276]




Development General population, Danish National Cohort No difference in the development of newborns from mothers
with high PFOA and PFOS concentrations and children of mothers
with low PFOA and PFOS concentrations; sitting without support






General population, USA Weak inverse correlation between concentrations of PFOS and




General population, Japan No correlation between PFOS concentration in cord blood and
concentration of thyroid hormones
Inoue et
al. [54]




General population, USA, 2000 to 2006 Weak association of PFOA and PFOS serum concentrations with
the occurrence of preeclampsia
Stein et al.
[276]
General population, 571 children between 12 to 15
years from the NHANES study, 1999 to 2000 and
2003 to 2004
Increased risk of ADHD for children with elevated PFOS, PFOA,
PFHxA, and PFNA serum concentrations
Hoffman
et al. [280]
Fertility General population, Danish National Birth Cohort,
1996 to 2002
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on human fetal development. The authors compared the
published results, listed the strengths and weaknesses,
listed alternative possible explanations for published
results, and suggested future studies. They came to the
conclusion that future research activities on this subject
will need to consider more carefully the physiology of
pregnant mothers and the increased maternal plasma
volume during pregnancy. In addition, participants from
the general population with the highest PFOS and
PFOA concentrations should be included in order to
better recognize possible toxic effects [281].
Steenland et al. [282] also published a review of epide-
miological studies on PFOA. The authors concluded
that available studies provide consistent evidence of a
weakly positive association of the PFOA concentration
in serum with cholesterol and the uric acid levels,
whereby the magnitude of the effect on cholesterol level
is not correlated with the extent of exposure.
Apart from that, there are a few but inconsistent indi-
cations of a weakly positive correlation with the activ-
ities of liver enzymes. A majority of the results stem
from cross-sectional analyses from which it is not possi-
ble to draw conclusions of causality. Two cohort studies
of occupationally exposed workers do not provide
unequivocal evidence of chronic disease; however, as a
result of the small numbers of participants, the informa-
tion they provide is limited.
There is a recent upturn in the number of publica-
tions on reproductive effects. The results from these
studies are, however, inconsistent, and the observed
adverse effects are weak. It is therefore concluded that
the information provided by the results from previous
epidemiological studies is limited and the data is inade-
quate to allow unambiguous conclusions to be drawn
about the role of PFOA in the development of particular
diseases [282].
Summary
The present general opinion is that the main route of
PFC uptake is dietary with contaminated fish and game,
constituting a majority of the exposure. Nonetheless, the
representative data that would allow an estimation of
dietary exposure is not available. Therefore, in 2009, the
EU launched the research project, PERFOOD, with the
aim of improving the level of awareness about PFCs in
foods. Among other things, the migration of PFCs from
packaging material into foodstuffs is also to be studied.
Additionally, other less studied pathways such as skin
contact with PFC-treated utensils and inhalation of
indoor air in particular should also be further studied.
Comparatively, little data is, however, presently available
on these paths of exposure. According to previous stu-
dies, the total daily PFC uptake is in the range of 2 to
200 ng/kg BW/day for PFOS and 3 to 14 ng/kg BW/day
for PFOA. Admittedly, other PFCs such as FTOH or
FOSE/FOSA may contribute to the internal contamina-
tion of humans. As a result of their lower body mass
and increased hand-to-mouth contact, it may be
assumed that the internal PFC contamination per kilo-
gram body mass of children is greater than that of
adults. In addition, PFOS and PFOA can cross the pla-
cental barrier and can pass into breast milk.
The quantitatively dominant component of PFCs in
the human blood is PFOS. The PFOA concentrations
are generally somewhat lower in the blood than PFOS
concentrations. The linear forms of both so-called refer-
ence components are most commonly identifiable in
blood samples. Geographic differences have been found
for PFC serum concentrations in humans. Individual
studies show a possible influence of diet on the degree
of contamination with PFCs. An unequivocal correlation
between age and blood PFC concentration is not evi-
dent. Gender-dependent differences are, however, prob-
able. Men generally show a higher contamination with
PFCs than women. The serum concentrations of these
compounds appear to have risen over the last decades.
Whether this trend will continue is presently unknown.
Animal experiments suggest that PFCs are relatively
well taken up by the organism both orally and by inha-
lation. They accumulate primarily in the liver, and after
increasing exposure, also in the blood, and other organs
such as the kidneys. An explanation of the mechanism
by which this distribution takes place involves the pre-
ferred binding of PFCs to serum albumin, L-FABP, and
membrane structures in the liver. There is presently no
evidence for metabolism of PFOS or PFOA. In contrast,
there is increasing evidence for metabolism of FTOH.
Differences in the excretion of PFCs have been found
for different compounds and different species. PFOS is
excreted more slowly than PFOA so that the latter has a
shorter elimination half-life and higher rate of excretion.
It can be assumed that branched chain molecules are
more rapidly excreted than the linear isomers, which
therefore tend to accumulate more. According to cur-
rent knowledge, short-chain PFCs such as PFBS are also
excreted more rapidly than long-chain PFCs. An active
and sex-hormone-regulated mechanism for renal excre-
tion of PFOA has been demonstrated in rats. Enterohe-
patic circulation appears to reduce the excretion rate of
PFOS and PFOA as also shown in an experiment on
rats.
Based on the results of animal experiments, the acute
toxicity is considered modest. Diverse toxic effects were
observed in longer-term animal tests. Hepatotoxic
effects have often been described. In addition, lipid
metabolism was often affected in experimental animals.
Epidemiological studies have indicated effects of PFCs
on glucose, urea, and/or uric acid metabolism; therefore,
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it would seem that further studies on PFCs and meta-
bolic processes are necessary. Tumor growth has been
observed in experimental animals after chronic expo-
sure. Most commonly the liver, Leydig cells, and mam-
mary gland tissue have been involved. Evidence of the
occurrence of particular cancer diseases, most often
urinary bladder and prostrate cancers, have been
observed in individual epidemiological studies. The tar-
get organs of animals and humans appear to differ,
aside from the pancreas that was seen to be prone to
cancerous growth both in humans and in animals. In
regard to carcinogenesis, a genotoxic mechanism cannot
be assumed for PFOS and PFOA, but rather a tumor
promoting effect and/or epigenetic process come into
question. Animal studies show unmistakable reproduc-
tive and developmental toxic effects that were only par-
tially found in epidemiological studies. There is
presently no evidence of teratogenic effects. To more
thoroughly understand the influence on human fertility
and the development of newborn children, the results
on reproductive toxicity from animal studies should be
taken into consideration. Considering the results of ani-
mal experiments, neuro- and immunotoxic effects will
have to be examined in future epidemiological studies.
The trigger for hepato- and immuno-reproductive,
reproductive, and developmental effects as well as carci-
nogenesis of PFCs may be partially or completely attrib-
uted to the activation of the PPARa. Correspondingly, a
change in expression of the genes that control lipid
metabolism, energy homeostasis, cell differentiation, and
peroxisome proliferation might be involved.
Apparently, different PFCs exhibit different toxicities.
PFOS and linear isomers appear to be more toxic than
PFOA and branched chain compounds, i.e., in compari-
son, PFOS and linear isomers exhibit a longer half-life
than do PFOA and branched chain compounds and
cause adverse effects at lower dosages. The data pre-
sently available regarding toxicology of PFCs other than
PFOS and PFOA is in comparison meager, inhomoge-
neous, and fragmentary, particularly in light of the
diversity of PFCs occurring in biological matrices.
Conclusions
There are a number of pathways by which PFC contam-
ination of humans can take place including diet, food
contact materials, non-food personal items, and indoor
and outdoor air. Although a number of authors have
attempted to calculate the contribution of these indivi-
dual pathways to total contamination, the available data
records are not presently adequate to allow sound con-
clusions to be drawn. In addition, the various authors
have, to some extent, taken diverse approaches to the
subject of dietary contamination. Some have assumed
that consumption of fish and seafood are the main
source of PFC contamination in humans, whereas
others have postulated that, particularly in regions in
which only small amounts of fish are eaten, meat and
vegetables are the primary source. There is, however, a
general consensus that dietary uptake represents the lar-
gest contribution. Nonetheless, it will be necessary to
establish the contribution of various foodstuffs to total
exposure by comparing the data from studies that sys-
tematically determine PFC contamination of a large
number of edible products. Studies that are limited to
local or regional products are not adequate to describe
the global exposure scenario. Toxicokinetic and toxico-
dynamic data of PFCs, aside from those for the so-
called reference substances, PFOA and PFOS, are not
consistent enough to allow a conclusive toxicological
evaluation.
In recent years, numerous publications have
appeared in which biological properties of PFCs are
described; however, these are generally limited to
PFOA and PFOS. These two substances are, to the
best of our knowledge, the only PFCs that have been
toxicologically examined in animal studies that would
allow conclusions to be drawn about potential human
toxicity. Data on short-chain PFCs that are apparently
being substituted for longer chain molecules in indus-
trial processes are, if available at all, only of a fragmen-
tary nature. Because of their solubility in water and the
increasingly wide spectrum and volume of their use,
these short-chain PFCs deserve considerable study.
This is particularly evident since they appear to be ubi-
quitously distributed throughout the water pathway
and can thus lead to an increased background contam-
ination of the environment. Additionally, PFCs are
being used in mixtures with varying compositions,
making toxicological evaluations much more difficult.
For this reason, standardized in vitro and in vivo meth-
ods should be used and further developed in order to
allow reliable conclusions to be drawn concerning the
toxicity of the individual substances as well as of var-
ious PFC mixtures. Consequently, an adequate toxico-
logical evaluation of the total situation is presently not
possible.
Endnotes
aThe LOD was not specified in the publication. bThe
type of average was not specified. cWhether the dose
was based on a kg BW is not evident from the descrip-
tion of the study. dCalculated according to the following
formula: bile clearance (mL/hr/kg BW) = PFOA in the
bile0-300 min (nmol)/AUC 0-300 min (nmol·hr/mL)/kg BW.
eThe age of the animals was not listed. fConcentrations
and locations were not listed. gMore details were not
presented. hThe types of congenital defects were not
described.
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